Evolent Health (EVH) 10-Q 9 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 06, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Evolent Health, Inc.
Entity Central Index Key	0001628908
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Class A
Entity Common Stock, Shares Outstanding (in shares)		81,963,259
Class B
Entity Common Stock, Shares Outstanding (in shares)		713,517

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 170,817	$ 228,320
Restricted cash and restricted investments	50,920	154,718
Accounts receivable, net (amounts attributable to related parties: 2019 - $8,701; 2018 - $8,519)	65,626	80,208
Prepaid expenses and other current assets (amounts attributable to related parties: 2019 - 0; 2018 - $85)	30,495	22,618
Investments, at amortized cost	2,046	0
Contract assets	1,282	2,102
Total current assets	321,186	487,966
Restricted cash and restricted investments	7,036	6,105
Investments, at amortized cost	11,743	10,010
Investments in and advances to equity method investees	6,188	6,276
Property and equipment, net	77,379	73,628
Right-of-use assets - operating	63,855
Prepaid expenses and other noncurrent assets (amounts attributable to related parties: 2019 - $3,500; 2018 - $2,500)	11,264	15,028
Contract assets	1,695	961
Contract cost assets	22,463	19,147
Intangible assets, net	336,231	335,036
Goodwill	770,334	768,124
Total assets	1,629,374	1,722,281
Current liabilities:
Accounts payable (amounts attributable to related parties: 2019 - $2,496; 2018 - $1,564)	39,007	146,760
Accrued liabilities (amounts attributable to related parties: 2019 - $1,462; 2018 - $798)	53,018	48,957
Operating lease liabilities - current	3,439
Accrued compensation and employee benefits	15,872	25,460
Deferred revenue	22,320	20,584
Reserve for claims and performance-based arrangements	30,019	27,595
Total current liabilities	163,675	269,356
Long-term debt, net of discount	223,320	221,041
Other long-term liabilities	10,490	17,090
Operating lease liabilities - noncurrent	57,197
Deferred tax liabilities, net	24,566	25,438
Total liabilities	479,248	532,925
Commitments and Contingencies (See Note 9)
Shareholders' Equity (Deficit)
Additional paid-in capital	1,096,089	1,093,174
Accumulated other comprehensive income (loss)	(158)	(182)
Retained earnings (accumulated deficit)	3,270	50,009
Total shareholders' equity (deficit) attributable to Evolent Health, Inc.	1,100,026	1,143,824
Non-controlling interests	50,100	45,532
Total shareholders' equity (deficit)	1,150,126	1,189,356
Total liabilities and shareholders' equity (deficit)	1,629,374	1,722,281
Class A
Shareholders' Equity (Deficit)
Common stock	794	792
Class B
Shareholders' Equity (Deficit)
Common stock	$ 31	$ 31

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounts receivable, related parties	$ 8,701	$ 8,519
Prepaid expenses and other current assets, related parties	0	85
Prepaid expenses and other noncurrent assets, related parties	3,500	2,500
Accounts payable, related parties	2,436	1,561
Accrued liabilities, related parties	$ 1,481	$ 798
Class A
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	750,000,000	750,000,000
Common stock, issued (in shares)	79,428,728	79,172,118
Common stock, outstanding (in shares)	79,428,728	79,172,118
Class B
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	100,000,000	100,000,000
Common stock, issued (in shares)	3,190,301	3,190,301
Common stock, outstanding (in shares)	3,190,301	3,190,301

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Revenue
Revenues		$ 197,756	$ 139,714
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)	[1]	117,441	71,975
Claims expenses		37,757	16,749
Selling, general and administrative expenses		74,838	55,526	[1]
Depreciation and amortization expenses		14,266	9,496
Change in fair value of contingent consideration		100	100
Total operating expenses		244,402	153,846
Operating income (loss)		(46,646)	(14,132)
Interest income		1,060	1,072
Interest expense		(3,562)	(853)
Income (loss) from equity method investees		(424)	(131)
Other income (expense), net		427	(18)
Income (loss) before income taxes and non-controlling interests		(49,145)	(14,062)
Provision (benefit) for income taxes		(496)	3
Net income (loss)		(48,649)	(14,065)
Net income (loss) attributable to non-controlling interests		(1,910)	(439)
Net income (loss) attributable to Evolent Health, Inc.		(46,739)	(13,626)
Earnings (Loss) Available for Common Shareholders
Basic and Diluted		$ (46,739)	$ (13,626)
Earnings (Loss) per Common Share
Basic and Diluted (in dollars per share)		$ (0.59)	$ (0.18)
Weighted-Average Common Shares Outstanding
Basic and Diluted (in shares)		79,335	75,375
Comprehensive income (loss)
Net income (loss)		$ (48,649)	$ (14,065)
Other comprehensive income (loss), net of taxes, related to:
Foreign currency translation adjustment		24	0
Total comprehensive income (loss)		(48,625)	(14,065)
Total comprehensive income (loss) attributable to non-controlling interests		(1,910)	(439)
Total comprehensive income (loss) attributable to Evolent Health, Inc.		(46,715)	(13,626)
Transformation services
Revenue
Revenues	[1]	3,353	6,505
Platform and operations services
Revenue
Revenues		147,292	109,818	[1]
Premiums
Revenue
Revenues		$ 47,111	$ 23,391
[1]	See Note 17 for amounts related to related parties included in these line items.

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows from Operating Activities
Net income (loss)	$ (48,649)	$ (14,065)
Adjustments to reconcile net income (loss) to net cash and restricted cash provided by (used in) operating activities:
(Income) loss from equity method investees	424	131
Change in fair value of contingent consideration	100	100
Depreciation and amortization expenses	14,266	9,496
Amortization of deferred financing costs	2,279	229
Stock-based compensation expense	4,537	3,795
Deferred tax provision (benefit)	(492)	(42)
Amortization of contract cost assets	1,250	570
Other	427	(206)
Changes in assets and liabilities, net of acquisitions:
Accounts receivables, net and contract assets	14,796	(17,135)
Prepaid expenses and other current and noncurrent assets	(4,174)	(12,610)
Contract cost assets	(4,565)	(355)
Accounts payable	(204)	2,334
Accrued liabilities	3,605	5,209
Accrued compensation and employee benefits	(9,591)	(19,570)
Deferred revenue	1,736	10,869
Reserves for claims and performance-based arrangements	2,424	6,699
ROU operating assets	(12,493)
Operating lease liabilities	13,233
Other long-term liabilities	(4,618)	(154)
Net cash and restricted cash provided by (used in) operating activities	(25,709)	(24,705)
Cash Flows from Investing Activities
Cash paid for asset acquisitions or business combinations	(6,000)	(11,676)
Customer advance for regulatory capital requirements	(5,400)	0
Principal repayment of implementation funding loan	0	4,000
Amount received from escrow in asset acquisition	0	500
Purchases of investments	(3,779)	0
Investments in and advances to equity method investees	(337)	(4,000)
Investments in internal-use software and purchases of property and equipment	(9,462)	(9,553)
Purchases of restricted investments	(500)	0
Maturities of restricted investments	0	8,044
Net cash and restricted cash provided by (used in) investing activities	(25,478)	(12,685)
Cash Flows from Financing Activities
Changes in working capital balances related to claims processing on behalf of partners	(107,500)	(22,268)
Amount received from escrow in asset acquisition	500	0
Deferred financing costs related to 2025 Notes	(608)	0
Proceeds from stock option exercises	123	1,461
Taxes withheld and paid for vesting of restricted stock units	(2,180)	(800)
Net cash and restricted cash provided by (used in) financing activities	(109,665)	(21,607)
Effect of exchange rate on cash and cash equivalents and restricted cash	(19)	(4)
Net increase (decrease) in cash and cash equivalents and restricted cash	(160,871)	(59,001)
Cash and cash equivalents and restricted cash as of beginning-of-period	388,325	295,363
Cash and cash equivalents and restricted cash as of end-of-period	$ 227,454	$ 236,362

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common StockClass A	Common StockClass B	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Non-controlling Interests
Beginning balance (in shares) at Dec. 31, 2017		74,723	2,654
Beginning balance, amount at Dec. 31, 2017	$ 1,046,306	$ 747	$ 27	$ 924,153	$ 0	$ 85,952	$ 35,427
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	3,795			3,795
Exercise of stock options (in shares)		354
Exercise of stock options	1,461	$ 4		1,457
Restricted stock units vested, net of shares withheld for taxes (in shares)		129
Restricted stock units vested, net of shares withheld for taxes	(800)	$ 1		(801)
Exchange of Class B common stock (in shares)		1,773	(1,773)
Exchange of Class B common stock	0	$ 18	$ (18)	23,805			(23,805)
Tax impact of Class B Exchanges	908			908
Foreign currency translation adjustment	0			0	0	0	0
Net income (loss)	(14,065)					(13,626)	(439)
Reclassification of non-controlling interests				5			(5)
Ending balance (in shares) at Mar. 31, 2018		76,979	881
Ending balance, amount at Mar. 31, 2018	1,054,914	$ 770	$ 9	953,322	0	89,041	11,772
Beginning balance (in shares) at Dec. 31, 2018		79,172	3,190
Beginning balance, amount at Dec. 31, 2018	1,189,356	$ 792	$ 31	1,093,174	(182)	50,009	45,532
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	4,152			4,152
Exercise of stock options (in shares)		11
Exercise of stock options	123	$ 0		123
Restricted stock units vested, net of shares withheld for taxes (in shares)		203
Restricted stock units vested, net of shares withheld for taxes	(2,180)	$ 2		(2,182)
Class A common stock issued for Passport earn-out (in shares)		43
Class A common stock issued for Passport earn-out	800	$ 0		800
Amount attributable to NCI from 2019 business combination	6,500						6,500
Foreign currency translation adjustment	24				24
Net income (loss)	(48,649)			0	0	(46,739)	(1,910)
Reclassification of non-controlling interests				22			(22)
Ending balance (in shares) at Mar. 31, 2019		79,429	3,190
Ending balance, amount at Mar. 31, 2019	$ 1,150,126	$ 794	$ 31	$ 1,096,089	$ (158)	$ 3,270	$ 50,100

Organization

Organization	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware, and is a managed care services firm that supports leading health systems and physician organizations in their migration toward value-based care and population health management. The Company operates through two segments. The Company’s services segment (“Services”) provides our customers, who we refer to as partners, with a population health management platform, integrated data and analytics capabilities, claims processing services, pharmacy benefit management, specialty care management services and comprehensive health plan administration services. Together these services enable health systems to manage patient health in a more cost-effective manner. The Company’s contracts are structured as a combination of advisory fees, monthly member service fees, percentage of plan premiums and shared medical savings arrangements. The Company’s wholly-owned subsidiary, True Health New Mexico, Inc. (“True Health”) operates as a separate segment and is a commercial health plan we operate in New Mexico that focuses on small and large businesses. The Company’s headquarters is located in Arlington, Virginia. As of March 31, 2019 , Evolent Health, Inc. owns 96.1% of Evolent Health LLC, holds 100% of the voting rights, is the sole managing member and controls its operations. Therefore, the financial results of Evolent Health LLC have been consolidated in the financial statements of Evolent Health, Inc. Since its inception, the Company has incurred losses from operations. As of March 31, 2019 , the Company had cash and cash equivalents of $170.8 million . The Company believes it has sufficient liquidity for the next 12 months as of the date the financial statements were available to be issued.

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles	Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2018 , has been derived from audited financial statements as of that date. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2018 Form 10-K. Summary of Significant Accounting Policies Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 2” in our 2018 Form 10-K for a complete summary of our significant accounting policies. Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles and long-lived assets), liabilities (including IBNR), consideration related to business combinations and asset acquisitions, revenue recognition including variable consideration, estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, contingent payments, allowance for doubtful accounts, depreciable lives of assets, impairment of long lived assets (including equity method investments), stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, valuation of intangible assets (including goodwill), purchase price allocation in taxable stock transactions and the useful lives of intangible assets. Principles of Consolidation The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. Operating Segments Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company operates through two segments: (1) Services, and (2) True Health. Our Services segment consists of our technology-enabled value-based care services, specialty care management services and comprehensive health plan administration services. Our True Health segment consists of a commercial health plan we operate in New Mexico that focuses on small and large businesses. See Note 18 for a discussion of our operating results by segment. Revenue Recognition Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan strategy. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management (through performance-based arrangements) and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily third-party administration (“TPA”) services. Revenue is recognized when control of the services is transferred to our customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition for our Services segment from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. True Health also derives revenue from reinsurance premiums assumed from NMHC under the terms of the Reinsurance Agreement (as defined in Note 9 ). The portion of premiums that will be earned in the future or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as short-term deferred revenue on our consolidated balance sheets. See Note 5 for further discussion of our policies related to revenue recognition. Leases As discussed in Note 3 , we adopted Accounting Standards Update (“ASU”) 2016-02 effective January 1, 2019. The following reflects our updated policy for leases. The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on the balance sheet. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is offset against rent expense over the terms of the respective leases. Refer to Note 10 for additional lease disclosures. Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: As of As of March 31, December 31, 2019 2018 Collateral for letters of credit for facility leases (1) $ 3,710 $ 3,710 Collateral with financial institutions (2) 37,691 34,142 Claims processing services (3) 14,939 122,439 Other 1,616 532 Total restricted cash and restricted investments 57,956 160,823 Current restricted investments 711 211 Current restricted cash 50,209 154,507 Total current restricted cash and restricted investments 50,920 154,718 Noncurrent restricted investments 608 607 Noncurrent restricted cash 6,428 5,498 Total noncurrent restricted cash and restricted investments $ 7,036 $ 6,105 (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 9 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements. As of March 31, 2019 , and December 31, 2018 , approximately $34.8 million and $31.2 million of the collateral amount was in a trust account and invested in a money market fund. The amounts invested in money market funds are considered restricted cash and are carried at fair value, which approximates cost. See Note 16 for discussion of our fair value measurement and Note 9 for discussion of our risk-sharing arrangements. As of March 31, 2019 , and December 31, 2018 , approximately $2.9 million of the collateral amount was held in FDIC participating bank accounts, primarily related to a line of credit. (3) Represents cash held by Evolent related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. As of March 31, 2019 2018 Cash and cash equivalents $ 170,817 $ 200,316 Restricted cash and restricted investments 57,956 36,757 Restricted investments included in restricted cash and restricted investments (1,319 ) (711 ) Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 227,454 $ 236,362 Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred. Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level, which is consistent with the way management evaluates our business. The Company has three reporting units: Legacy Services, New Century Health and True Health. Our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. Information regarding the determination and allocation of the fair value of recently acquired assets and liabilities is further described within Note 4 . The following summarizes the estimated useful lives by asset classification: Corporate trade name 10-20 years Customer relationships 10-25 years Technology 5 years Provider network contracts 5 years Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 7 for additional discussion regarding our intangible assets. Reserves for claims and performance-based arrangements Reserves for claims and performance-based arrangements for our Services and True Health segments reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed to NMHC under a reinsurance agreement as discussed further in Note 9 . The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 19 for additional discussion regarding our reserves for claims and performance-based arrangements. Foreign Currency The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. Foreign currency translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2019 and 2018 .

Recently Issued Accounting Stan

Recently Issued Accounting Standards	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards Adoption of New Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases , in order to establish the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This update introduces a new standard on accounting for leases, including a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in ASC 606. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, which is intended to make targeted improvements to ASU 2016-02. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard using an effective date method rather than the earliest comparative period. The requirements of ASU 2018-11 are effective on the same date as the requirements of ASU 2016-02. We adopted ASU 2016-02 as of January 1, 2019, using the modified retrospective approach. Further, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of additional right-of-use assets and lease liabilities of approximately $51.4 million and $47.4 million , respectively, on our consolidated balance sheet as of January 1, 2019. The standard had no impact on our results of operations. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Services Contract . The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted the requirements of ASU 2018-15 effective January 1, 2019. There was no impact to our consolidated balance sheets or results of operations as of or for the three months ended March 31, 2019 . In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers , in order to clarify the principles of recognizing revenue. This standard establishes the core principle of recognizing revenue to depict the transfer of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB defines a five-step process that systematically identifies the various components of the revenue recognition process, culminating with the recognition of revenue upon satisfaction of an entity’s performance obligations. By completing all five steps of the process, the core principles of revenue recognition will be achieved. The new revenue standard (including updates) is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016. The guidance permits two methods of adoption: i) the full retrospective method applying the standard to each prior reporting period presented, or ii) the modified retrospective method with a cumulative effect of initially applying the guidance recognized at the date of initial application. The standard also allows entities to apply certain practical expedients at their discretion. The Company adopted the standard effective January 1, 2018, using the modified retrospective method for only contracts that were not completed at the date of initial application. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (“ASC 605”). The adoption of this standard resulted in changes related to revenue recognition for contracts that contain certain features, such as variable consideration. These changes generally accelerate revenue recognition. In addition, certain customer setup costs, which have historically been expensed as incurred, will now be capitalized. Evolent recognized the cumulative effect of applying the new revenue standard as a $17.3 million adjustment to the opening balance of retained earnings, including non-controlling interests, in the first quarter of 2018, primarily as a result of capitalization of expenses related to contract acquisition and fulfillment costs and acceleration of revenue due to variable consideration estimation. See Note 5 for additional disclosures regarding Evolent's contracts with customers. See Note 2 for updated revenue recognition accounting policy. Future Adoption of New Accounting Standards In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments . With respect to assets measured at amortized cost, such as held-to-maturity assets, the update requires presentation of the amortized cost net of a credit loss allowance. The update eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity’s current estimate of all future expected credit losses as opposed to the previous standard, when an entity only considered past events and current conditions. With respect to available for sale debt securities, the update requires that credit losses be presented as an allowance rather than as a write-down. The update is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We intend to adopt the requirements of this standard effective January 1, 2020, and are currently evaluating the impact of the adoption on our financial condition and results of operations.

Transactions

Transactions	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Transactions	Transactions Business Combinations New Century Health On October 1, 2018 , the Company completed its acquisition of New Century Health, including 100% of the voting equity interests. New Century Health is a technology-enabled, specialty care management company focused primarily on cancer and cardiac care and its assets include a proprietary technology platform which brings together clinical capabilities, pharmacy management and physician engagement to assist New Century Health’s customers in managing the large and complex specialties of cancer and cardiac care. We expect that the transaction will allow Evolent to enhance its clinical capabilities and enable it to offer a more integrated set of services to its current provider partners. Total merger consideration, net of cash on hand and certain closing adjustments, was $205.1 million , based on the closing price of the Company’s Class A common stock on the NYSE on October 1, 2018 . The merger consideration consisted of $118.7 million of cash consideration, 3.1 million shares of Evolent Health LLC’s Class B common units and an equal number of the Company’s Class B common stock and an earn-out of up to $11.4 million , fair valued at $3.2 million as of October 1, 2018 . The merger agreement includes an earn-out of up to $20.0 million , $11.4 million of which is payable to the former owners of New Century Health and $8.6 million of which is payable to former employees of New Century Health that became employees of the Company. The amount payable to the former owners of New Century Health is considered merger consideration. The amount payable to the former employees of New Century Health requires continued employment with the Company and is therefore considered post-combination compensation expense. See Note 16 for additional information regarding the fair value determination of the earn-out consideration and “Part II - Item 8. Financial Statements and Supplementary Data - Note 11” within our 2018 Form 10-K for additional information about the portion of the earn-out that is classified as post-combination compensation expense. The Evolent Health LLC Class B common units, together with a corresponding number of the Company’s Class B common stock, can be exchanged for an equivalent number of the Company’s Class A common stock, and were valued at $83.2 million using the closing price of the Company’s Class A common stock on the NYSE on October 1, 2018 . As a result of the Class B common stock issued for the New Century Health transaction, the Company’s ownership in Evolent Health LLC decreased from 99.0% to 95.3% , immediately following the acquisition. The Company incurred approximately $1.6 million of transaction costs related to the New Century Health transaction during 2018, which are recorded within “Selling, general and administrative expenses” on our consolidated statements of operations and comprehensive income (loss). The Company accounted for the transaction as a business combination using the acquisition method of accounting. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2018 , as follows (in thousands): Purchase consideration: Cash $ 124,652 Fair value of Class B common stock issued 83,173 Fair value of contingent consideration 3,200 Total consideration $ 211,025 Tangible assets acquired: Cash and cash equivalents $ 5,963 Accounts receivable 5,559 Prepaid expenses and other current assets 7,901 Property and equipment 381 Other noncurrent assets 148 Identifiable intangible assets acquired: Customer relationships 72,500 Technology 27,000 Corporate trade name 4,300 Provider network contracts 9,600 Liabilities assumed: Accounts payable 1,167 Accrued liabilities 1,494 Accrued compensation and employee benefits 3,966 Reserves for claims and performance-based arrangements 18,631 Deferred tax liabilities 24,041 Other long-term liabilities 6,138 Goodwill 133,110 Net assets acquired $ 211,025 The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships will be amortized on a straight-line basis over their preliminary estimated useful lives of 15 years. Identifiable intangible assets associated with technology, corporate trade name and provider network contracts will be amortized on a straight-line basis over their preliminary estimated useful lives of 5 , 10 and 5 years, respectively. The customer relationships are primarily attributable to long-term existing contracts with current customers. The technology consists of a clinical rules engine portal, data warehouse and claims system that New Century Health uses to provide services to its customers. The corporate trade name reflects the value that the New Century Health brand name carries in the market. The provider network contracts represents the established provider network that New Century Health relies on to provide services to its customers. The fair value of the intangible assets was determined using the income approach, the relief from royalty approach and the cost approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. The cost approach estimates the fair value of an asset by determining the amount that would be required currently to replace the service capacity of an asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Services segment. Goodwill is considered to be an indefinite lived asset. The merger was structured as a tax-free reorganization and therefore the Company received carryover basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. The amounts above reflect management’s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed based on a valuation performed using currently available information. Any necessary adjustments will be finalized within one year from the date of acquisition. New Mexico Health Connections On January 2, 2018 , the Company, through its wholly-owned subsidiary, True Health, completed its previously announced acquisition of assets related to NMHC’s commercial, small and large group business. The assets include a health plan management services organization with a leadership team and employee base with experience working locally with providers to run NMHC’s suite of preventive, disease and care management programs. The Company paid cash consideration of $10.3 million in connection with the acquisition. This acquisition is expected to allow the Company to leverage its platform to support a value-based, provider-centric model of care in New Mexico. The Company commenced operations of the commercial health plan and began reporting the results of True Health as a new reportable segment during the first quarter of 2018. See Note 18 for further information about the Company’s segments. At the time of the acquisition, the Company also entered into a managed services agreement (“MSA”) with NMHC to support its ongoing business. During the fourth quarter of 2017, the Company also entered into a reinsurance agreement with NMHC to provide balance sheet support. See Note 9 for further discussion of the reinsurance agreement. The MSA and reinsurance agreement were considered separate transactions and accounted for outside of the business combination. Therefore, there is no allocation of purchase price to these agreements at fair value. The Company incurred approximately $1.2 million in transaction costs related to the NHMC transaction, materially all of which were recorded within “Selling, general and administrative expenses” on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2017. The transaction was accounted for as a business combination using the acquisition method of accounting. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 2, 2018 , as follows (in thousands): Purchase consideration Cash paid to NMHC $ 10,000 Cash paid to escrow agent 252 Total consideration $ 10,252 Identifiable intangible assets acquired and liabilities assumed Customer relationships $ 2,700 Provider network contracts 2,300 Above market lease (100 ) Accrued compensation and employee benefits (474 ) Goodwill 5,826 Net assets acquired $ 10,252 Identifiable intangible assets associated with customer relationships and provider network contracts will be amortized on a straight-line basis over their estimated useful lives of 15 and 5 years, respectively. The customer relationships represent existing contracts in place to provide health plan services to a number of large and small group customers throughout the state of New Mexico. The provider network contracts represent a network of hospitals and physicians to service the health plan customers. The fair value of the customer relationship intangible asset was primarily determined using the income approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The fair value of the provider network intangible asset was primarily determined using the cost approach. The cost approach estimates the fair value for an asset based on the amount it would cost to replace the asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. Goodwill associated with the acquisition of assets from NMHC is allocated entirely to the True Health segment. The goodwill is attributable primarily to the acquired workforce and expected cost synergies, none of which qualify for recognition as a separate intangible asset. Goodwill is considered an indefinite-lived asset. The transaction is an asset acquisition for tax purposes, and as such the tax-basis in the acquired assets is equal to the book-basis fair value calculated and is recorded at the True Health legal entity. Therefore, no opening balance sheet deferred tax liability was recorded. The amount of goodwill determined for tax purposes is deductible. The amounts above reflect management’s estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed based on a valuation performed using information available at the date of the transaction. True Health is a separate segment, and its results of operations are provided in Note 18 - Segment Reporting. Pro Forma Financial Information (Unaudited) The unaudited pro forma consolidated statements of operations presented below gives effect to the New Century Health and True Health transactions as if they took place on January 1, 2017. The following pro forma information includes adjustments to: • Remove transaction costs related to the New Century Health transaction of $1.6 million recorded during 2018 and reclassify such amounts to 2017; • Record amortization expenses related to intangible assets beginning on January 1, 2017, for intangibles acquired as part of the New Century Health and True Health transactions; • Record revenue and expenses related to the NMHC MSA beginning January 1, 2017; • Record stock-based compensation expense beginning on January 1, 2017, for equity awards granted as part of the New Century Health transaction; and • Record the issuance of Class B common shares as part of the New Century Health transaction as of January 1, 2017. This pro forma data is presented for informational purposes only and does not purport to be indicative of the results of future operations or of the results that would have occurred had the transactions described above occurred in the specified prior periods. The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company’s historical financial information on a pro forma basis (in thousands, except per share data). For the Three Months Ended March 31, 2019 2018 Revenue $ 197,756 $ 184,630 Net income (loss) (48,649 ) (14,885 ) Net income (loss) attributable to non-controlling interests (1,881 ) (972 ) Net income (loss) attributable to Evolent Health, Inc. (46,768 ) (13,913 ) Net income (loss) per Common Share available to common shareholders Basic and Diluted $ (0.59 ) $ (0.18 ) Securities Offerings and Sales Under an exchange agreement we entered into at the time of our IPO, we granted TPG, The Advisory Board Company (“The Advisory Board”) and Ptolemy Capital, LLC (“Ptolemy Capital”) (together, the “Investor Stockholders”) an exchange right that allows receipt of newly-issued shares of the Company’s Class A common stock in exchange (a “Class B Exchange”) for an equal number of shares of the Company’s Class B common stock (which are subsequently canceled) and an equal number of Evolent Health LLC’s Class B common units (“Class B units”). Class B units received by the Company from relevant Investor Stockholders are simultaneously exchanged for an equivalent number of Class A units of Evolent Health LLC, and Evolent Health LLC cancels the Class B units it receives in the Class B Exchange. The cancellation of the Class B units results in an increase in the Company’s economic interest in Evolent Health LLC. 2018 Private Sales In March 2018, The Advisory Board sold 3.0 million shares of the Company’s Class A common Stock in a private sale (the “March 2018 Private Sale”). The shares sold in the March 2018 Private Sale consisted of 1.2 million existing shares of the Company’s Class A common stock owned by The Advisory Board and 1.8 million newly-issued shares of the Company’s Class A common stock received by The Advisory Board pursuant to a Class B Exchange for all of its outstanding shares of the Company’s Class B common stock and Class B units. The Company did not receive any proceeds from the March 2018 Private Sale. Subsequent to this Class B Exchange, in June 2018, The Advisory Board sold all of their remaining shares of the Company’s Class A common stock and no longer owns any shares of our Class A common stock, Class B common stock or Class B units held by the Advisory Board at the time of the IPO. As a result of this Class B Exchange and Evolent Health LLC’s cancellation of the Class B units during the March 2018 Private Sale, the Company’s economic interest in Evolent Health LLC increased from 96.6% to 98.9% immediately following the March 2018 Private Sale, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. In November 2018, TPG sold 0.8 million shares of the Company’s Class A common stock in a number of private sales (the “November 2018 Private Sales”). The shares sold in the November 2018 Private Sales consisted of 0.1 million existing shares of the Company’s Class A common stock owned by TPG and 0.7 million newly-issued shares of the Company’s Class A common stock received by TPG pursuant to Class B Exchanges. The Company did not receive any proceeds from the November 2018 Private Sales. These sales represented all of TPG’s remaining equity interest in the Company and TPG no longer owns any of the shares of the Company’s Class A common stock, Class B common stock or Evolent Health LLC Class B common units held by TPG at the time of the IPO. As a result of these Class B Exchanges and Evolent Health LLC’s cancellation of the Class B common units during the November 2018 Private Sales, the Company’s economic interest in Evolent Health LLC increased from 95.3% to 96.1% immediately following the November 2018 Private Sales, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. The Company’s economic interest in Evolent Health LLC will increase if further Class B Exchanges occur.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation Services Revenue Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan strategy. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation. Platform and Operations Services Revenue Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management (through performance-based arrangements) and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically include a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue for platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs Agent We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement. Disaggregation of Revenue The following table represents Evolent’s Services segment revenue disaggregated by revenue type (in thousands), excluding revenues from our True Health segment and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, Financial Services-Insurance . For the Three Months Ended March 31, 2019 2018 Services Revenue Transformation services $ 3,353 $ 6,505 Platform and operations services 147,292 108,420 Transaction Price Allocated to the Remaining Performance Obligations For contracts with a term that is greater than one year, we have allocated approximately $84.6 million of transaction price to performance obligations that are unsatisfied or partially unsatisfied as of March 31, 2019 . We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2 . We expect to recognize revenue on approximately 56% and 88% of these remaining performance obligations by December 31, 2019, and December 31, 2020, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of this revenue that we actually receive may be less than this estimate and the timing of recognition may not be as expected. Contract Balances Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or noncurrent based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within “Contract assets” on our consolidated balance sheets. Our current accounts receivable are classified within “Accounts receivable, net” on our consolidated balance sheets and our noncurrent accounts receivable are classified within “Prepaid expenses and other noncurrent assets” on our consolidated balance sheets. Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or noncurrent based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within “Deferred revenue” on our consolidated balance sheets, and noncurrent deferred revenue is recorded within “Other long-term liabilities” on our consolidated balance sheets. The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): As of As of March 31, December 31, 2019 2018 Short-term receivables (1) $ 63,886 $ 78,380 Long-term receivables (1) 6,550 6,550 Short-term contract assets 1,282 2,102 Long-term contract assets 1,695 961 Short-term deferred revenue 22,320 20,584 Long-term deferred revenue 443 1,502 (1) Excludes pharmacy claims receivable and premiums receivable Changes in contract assets and deferred revenue for the three months ended March 31, 2019 , were as follows (in thousands): Contract assets Balance as of beginning-of-period $ 3,063 Reclass to receivables, as the right to consideration becomes unconditional (1,183 ) Contract assets recognized, net of reclass to receivables 1,097 Balance as of end-of-period $ 2,977 Deferred revenue Balance as of beginning-of-period $ 22,086 Reclass to revenue, as a result of performance obligations satisfied (11,807 ) Cash received in advance of satisfaction of performance obligations 12,484 Balance as of end-of-period $ 22,763 The amount of revenue recognized during the three months ended March 31, 2019 , from performance obligations satisfied (or partially satisfied) in previous periods was immaterial. Contract Cost Assets Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as noncurrent assets and recorded within “Contract cost assets” on our consolidated balance sheets. Amortization expense is recorded within “Selling, general and administrative expenses” on the accompanying consolidated statements of operations and comprehensive income (loss). As of March 31, 2019 and December 31, 2018 , the Company had $2.5 million and $1.5 million of contract acquisition cost assets, net of accumulated amortization. The Company recorded amortiza tion expense of $0.1 million and less than $0.1 million for the three months ended March 31, 2019 and 2018 , respectively. In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as noncurrent and recorded within “Contract cost assets” on our consolidated balance sheets. Amortization expense is recorded within “Cost of revenue” on the accompanying consolidated statements of operations and comprehensive income (loss). As of March 31, 2019 and December 31, 2018 , the Company had $20.0 million and 17.6 million of contract fulfillment cost assets, net of accumulated amortization. The Company recorded amortization expense of $1.2 million and $0.5 million for the three months ended March 31, 2019 and 2018 , respectively. The majority of the contract cost balance was recorded as part of the transition adjustment that was recorded upon implementation of ASC 606. These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net The following summarizes our property and equipment (in thousands): As of As of March 31, December 31, 2019 2018 Computer hardware $ 10,850 $ 10,421 Furniture and equipment 3,226 3,187 Internal-use software development costs 90,284 81,640 Leasehold improvements 10,011 10,118 Total property and equipment 114,371 105,366 Accumulated depreciation and amortization (36,992 ) (31,738 ) Total property and equipment, net $ 77,379 $ 73,628 The Company capitalized $8.7 million and $10.5 million of internal-use software development costs for the three months ended March 31, 2019 and 2018 , respectively. The net book value of capitalized internal-use software development costs was $67.4 million and $62.8 million as of March 31, 2019 , and December 31, 2018 , respectively. Depreciation expense related to property and equipment was $5.2 million for the three months ended March 31, 2019 , of which amortization expense related to capitalized internal-use software development costs was $4.1 million . Depreciation expense related to property and equipment was $3.6 million for the three months ended March 31, 2018 , of which amortization expense related to capitalized internal-use software development costs was $2.5 million .

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net Goodwill Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The Company has three reporting units: Legacy Services, New Century Health and True Health. Our annual goodwill impairment review occurs during the fourth quarter of each fiscal year. In interim periods between annual goodwill reviews, we also evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in strategy, partners, or litigation. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended March 31, 2019 . We will perform our annual impairment test as of October 31, 2019 . The following tables summarize the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands): For the Three Months Ended March 31, 2019 Services True Health Consolidated Balance as of beginning-of-period (1) $ 762,419 $ 5,705 $ 768,124 Goodwill Acquired 2,200 — 2,200 Measurement period adjustments — — — Foreign currency translation 10 — 10 Balance as of end-of-period $ 764,629 $ 5,705 $ 770,334 (1) Net of cumulative inception to date impairment of $160.6 million . For the Year Ended December 31, 2018 Services True Health Consolidated Balance as of beginning-of-period (1) $ 628,186 $ — $ 628,186 Goodwill Acquired (2) 134,343 5,826 140,169 Measurement period adjustments (3) 4 (121 ) (117 ) Foreign currency translation (4) (114 ) — (114 ) Balance as of end-of-period $ 762,419 $ 5,705 $ 768,124 (1) Net of cumulative inception to date impairment of $160.6 million . (2) Goodwill acquired primarily as a result of the New Century Health and True Health transactions, as discussed in Note 4 . (3) Measurement period adjustments related to transactions completed during the first quarter of 2018. (4) Foreign currency translation related to a transaction completed during the first quarter of 2018. Intangible Assets, Net Details of our intangible assets (in thousands) are presented below: As of March 31, 2019 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 14.9 $ 23,300 $ 3,856 $ 19,444 Customer relationships 17.6 291,519 32,818 258,701 Technology 2.7 82,922 36,261 46,661 Below market lease, net 3.8 4,097 3,037 1,060 Provider network contracts 4.4 11,900 1,535 10,365 Total $ 413,738 $ 77,507 $ 336,231 As of December 31, 2018 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 15.2 $ 23,300 $ 3,511 $ 19,789 Customer relationships 18.1 281,219 29,184 252,035 Technology 3.0 82,922 31,764 51,158 Below market lease, net 4.0 4,097 3,003 1,094 Provider network contracts 4.6 11,900 940 10,960 Total $ 403,438 $ 68,402 $ 335,036 Amortization expense related to intangible assets was $9.1 million and $5.9 million for the three months ended March 31, 2019 and 2018 , respectively. Future estimated amortization of intangible assets (in thousands) as of March 31, 2019 , is as follows: 2019 $ 28,419 2020 33,309 2021 29,173 2022 25,292 2023 22,528 Thereafter 197,510 Total $ 336,231 Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets’ carrying value. We did not identify any circumstances during three months ended March 31, 2019 , that would require an impairment test for our intangible assets.

Long-term Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt 2025 Notes In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended. The 2025 Notes were issued at par for net proceeds of $166.6 million . We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October 22, 2018 , and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October 24, 2018 , pursuant to the initial purchasers’ exercise in full of their option to purchase additional notes. Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019 , at a rate equal to 1.50% per annum. The Company recorded interest expense of $0.6 million related to the 2025 Notes for the three months ended March 31, 2019 . The 2025 Notes will mature on October 15, 2025 , unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding April 15, 2025 , the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October 22, 2018 , between the Company and U.S. Bank National Association, as trustee. At any time on or after April 15, 2025 , until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate. The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company’s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. The 2025 Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. The option to settle the 2025 Notes in cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be $100.7 million , before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million , before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $5.9 million are also allocated to the debt and equity components in proportion to the allocation of proceeds. Of the $5.9 million in issuance costs, $3.4 million of issuance costs is allocated to the debt component which, along with the equity component of $71.8 million , will be amortized to non-cash interest expense using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. For the three months ended March 31, 2019 , the Company recorded $2.0 million in non-cash interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component. Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October 20, 2022 . The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October 20, 2022 , if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. 2021 Notes In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the “2021 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended. The 2021 Notes were issued at par for net proceeds of $120.4 million . We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December 5, 2016 . Holders of the 2021 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2017 , at a rate equal to 2.00% per annum. The 2021 Notes will mature on December 1, 2021 , unless earlier repurchased or converted in accordance with their terms prior to such date. In addition, holders of the 2021 Notes may require the Company to repurchase their 2021 Notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the 2021 Notes being repurchased, plus any accrued and unpaid interest. Upon maturity, and at the option of the holders of the 2021 Notes, the principal amount of the notes may be settled via shares of the Company’s Class A common stock. For the three months ended March 31, 2019 and 2018 , the Company recorded approximately $0.6 million in interest expense and $0.2 million in non-cash interest expense related to the amortization of deferred financing costs. The 2021 Notes are convertible into shares of the Company’s Class A common stock, based on an initial conversion rate of 41.6082 shares of Class A common stock per $1,000 principal amount of the 2021 Notes, which is equivalent to an initial conversion price of approximately $24.03 per share of the Company’s Class A common stock. In the aggregate, the 2021 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change under the indenture between Evolent Health, Inc. and U.S. Bank National Association, as trustee, related to the 2.00% convertible senior notes due 2021, dated as of December 5, 2016). The 2021 Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, we will deliver for each $1,000 principal amount of notes converted a number of shares of our Class A common stock equal to the applicable conversion rate (together with a cash payment in lieu of delivering any fractional share) on the third business day following the relevant conversion date. Convertible Senior Notes Carrying Value The 2025 Notes and 2021 Notes are recorded on our accompanying unaudited interim consolidated balance sheets at their net carrying values of $100.8 million and $122.5 million , respectively, as of March 31, 2019 . However, the 2025 Notes and 2021 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act of 1933, as amended) and their fair values as of March 31, 2019 , were $136.7 million and $121.4 million , respectively, based on traded prices on April 3 , 2019, and March 28, 2019, respectively, which are Level 2 inputs. The fair values of the 2025 Notes and 2021 Notes as of December 31, 2018 , were $158.8 million and $133.6 million , respectively, based on traded prices on December 28, 2018, and December 26, 2018, respectively, which are Leve l 2 inputs. The 2025 Notes and 2021 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term debt (in thousands): As of As of March 31, December 31, 2019 2018 2025 Notes Carrying value $ 100,779 $ 98,730 Unamortized debt discount and issuance costs allocated to debt 71,721 73,770 Principal amount $ 172,500 $ 172,500 Remaining amortization period (years) 6.5 6.8 2021 Notes Carrying value $ 122,541 $ 122,311 Unamortized issuance costs 2,459 2,689 Principal amount $ 125,000 $ 125,000 Remaining amortization period (years) 2.7 2.9

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Commitments to Equity-Method Investees The Company has contractual arrangements with certain equity-method investees that will require the Company to provide operating capital and reserve support in the form of debt financing of up to $11.0 million as of March 31, 2019 and December 31, 2018 , in accordance with the Company’s contribution agreements with certain equity-method investees. These obligations are outside of Company’s control and payment could be requested during 2019. Letter of Credit During the first quarter of 2017, the Company entered into an agreement to provide a letter of credit, for up to $5.0 million , to assist a customer in demonstrating adequate reserves to the customer’s state regulatory authorities. The letter of credit is effective from September 30, 2017 through June 30, 2019, and carries a quarterly facility rental fee of 0.8% per annum on the amount of the outstanding balance. The letter of credit will terminate on June 30, 2019. The letter of credit is presented at the face amount plus accrued facility rental fee, less received payments. T here were no outstanding balances related t o this letter of credit as of March 31, 2019 , or December 31, 2018 . Lease Commitments The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. In connection with certain office space lease agreements, the Company is required to maintain $3.7 million in letters of credit and, as such, held $3.7 million in restricted cash and restricted investments as collateral for the letters of credit as of March 31, 2019 . Refer to Note 10 for additional discussion regarding leases. Indemnifications The Company’s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements. Pre-IPO Investor Registration Rights Agreement We entered into a registration rights agreement with The Advisory Board, the University of Pittsburgh Medical Center (“UPMC”), TPG and another investor to register for sale under the Securities Act of 1933, as amended, shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016. We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act of 1933, as amended, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our Investor Stockholders for the three months ended March 31, 2019 and 2018 . Guarantees As part of our strategy to support certain of our partners in the Next Generation Accountable Care Program, we entered into upside and downside risk sharing arrangements. Our downside risk-sharing arrangements are limited to our fees and are executed through our wholly-owned captive insurance company. To satisfy the capital requirements of our captive insurance entity as well as state insurance regulators, Evolent entered into letters of credit of $34.8 million as of March 31, 2019 , to secure potential losses related to insurance services. This amount is in excess of our actuarial assessment of loss. Reinsurance Agreements During the fourth quarter of 2017, the Company had entered into a 15 -month, $10.0 million capital-only reinsurance agreement with NMHC, which expired on December 31, 2018. The purpose of the capital-only reinsurance was to provide balance sheet support to NMHC. There was no uncertainty to the outcome of the agreement as there was no transfer of underwriting risk to Evolent or True Health, and neither Evolent nor True Health was at risk for any cash payments on behalf of NMHC. As a result, this agreement did not qualify for reinsurance accounting. The Company recorded a quarterly fee of approximately $0.2 million as non-operating income on its consolidated statements of operations and comprehensive income (loss) and maintained $10.0 million within “Restricted Cash and Restricted Investments” on its consolidated balance sheets for the duration of the reinsurance agreement. During the fourth quarter of 2018, the Company terminated its prior reinsurance agreement with NMHC and entered into a 15 -month quota-share reinsurance agreement with NMHC (“Reinsurance Agreement”). Under the terms of the Reinsurance Agreement, NMHC will cede 90% of its gross premiums to the Company and the Company will indemnify NMHC for 90% of its claims liability. The maximum amount of exposure to the Company is capped at 105% of premiums ceded to the Company by NMHC. The Reinsurance Agreement qualified for reinsurance accounting due to the deemed risk transfer and, as such, the Company will record the full amount of the gross reinsurance premiums and claims assumed by the Company within “Premiums” and “Claims Expenses,” respectively, and record claims-related administrative expenses within “Selling, general and administrative expenses” on our consolidated statements of operations and comprehensive income (loss) from the legal effective date of the Reinsurance Agreement. Amounts owed to NMHC under the Reinsurance Agreement are recorded within “Reserves for claims and performance-based arrangements” on our consolidated balance sheets. Amounts owed by NMHC under the Reinsurance Agreement are recorded within “Accounts receivable, net” on our consolidated balance sheets. The following table summarizes premiums and claims assumed under the Reinsurance Agreement for the three months ended March 31, 2019 (in thousands): Reinsurance premiums assumed $ 25,441 Claims assumed 21,151 Claims-related administrative expenses 4,282 (Increase) decrease in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement 8 Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period 1,243 Reinsurance payments 1,243 Receivables for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period $ 8 UPMC Reseller Agreement The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the “UPMC Reseller Agreement”). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company’s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company’s customers. Contingencies Tax Receivables Agreement In connection with the Offering Reorganization (as described in our 2018 Form 10-K), the Company entered into the Tax Receivables Agreement (the “TRA”) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. These payment obligations are obligations of the Company. For purposes of the TRA, the benefit deemed realized by the Company will be computed by comparing its actual income tax liability to the amount of such taxes that the Company would have been required to pay had there been no increase to the tax basis of the assets of the Company as a result of the exchanges or had the Company had no NOL carryforward balance. The actual amount and timing of any payments under the TRA will vary depending upon a number of factors, including: • the timing of the exchanges and the price of the Class A shares at the time of the transaction, triggering a tax basis increase in the Company’s asset and a corresponding benefit to be realized under the TRA; and • the amount and timing of our taxable income - the Company will be required to pay 85% of the tax savings as and when realized, if any. If the Company does not have taxable income, it will not be required to make payments under the TRA for that taxable year because no tax savings were actually realized. Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company’s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA. Litigation Matters We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. The Company is not aware of any legal proceedings or claims as of March 31, 2019 , that the Company believes will have, individually or in the aggregate, a material adverse effect on the Company’s financial position or result of operations. Credit and Concentration Risk The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of March 31, 2019 , approximately 80.3% of our $227.5 million of cash and cash equivalents (including restricted cash) were held in bank deposits with FDIC participating banks, approximately 19.3% were held in money market funds and less than 1.0% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date. The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes those partners who represented at least 10.0% of our trade accounts receivable for the periods presented: As of As of March 31, December 31, 2019 2018 Customer C 15.4 % 23.3 % In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners. The following table summarizes those partners who represented at least 10.0% of our revenue for the periods presented: For the Three Months Ended March 31, 2019 2018 Customer A 14.0 % * Customer B 13.1 % 20.1 % Customer C * 10.6 % * Represents less than 10.0% of the respective balance

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	Leases The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term or 12 months or less are not recorded on our consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is offset against rent expense over the terms of the respective leases. The following table summarizes the components of our lease expense (in thousands): For the Three Months Ended March 31, 2019 Operating lease cost $ 3,281 Variable lease cost 1,455 Total lease cost $ 4,736 As discussed in Note 3 , the Company adopted ASU 2016-02 effective January 1, 2019, which resulted in accounting for leases under ASC 842. Prior to the adoption, we accounted for leases under ASC 840. In accordance with ASC 840, rent expense, net of sublease income, on operating leases was $3.3 million for the three months ended March 31, 2018 . Maturity of lease liabilities (in thousands) as of March 31, 2019 , is as follows: Operating lease expense (1) 2019 $ 5,226 2020 8,613 2021 8,719 2022 7,563 2023 7,414 2024 and thereafter 47,118 Total lease payments 84,653 Less: Interest 24,017 Present value of lease liabilities 60,636 (1) We have additional operating lease agreements for office space that have not yet commenced as of March 31, 2019 . The minimum lease payments for those leases are $31.1 million and the leases will commence throughout the remainder of 2019. Our weighted-average discount rate and our weighted-remaining lease terms (in years) is as follows: As of March 31, 2019 Weighted average discount rate 6.25 % Weighted average remaining lease term 9.71

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Earnings (Loss) Per Common Share	Earnings (Loss) Per Common Share The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Three Months Ended March 31, 2019 2018 Net income (loss) $ (48,649 ) $ (14,065 ) Less: Net income (loss) attributable to non-controlling interests (1,910 ) (439 ) Net income (loss) available for common shareholders (1) (2) $ (46,739 ) $ (13,626 ) Weighted-average common shares outstanding (2) (3) 79,335 75,375 Earnings (Loss) per Common Share Basic $ (0.59 ) $ (0.18 ) Diluted (0.59 ) (0.18 ) (1) For periods of net loss, net income (loss) available for common shareholders is the same for both basic and diluted purposes. (2) Each Class B common unit of Evolent Health LLC can be exchanged (together with a corresponding number of shares of our Class B common stock) for one share of our Class A common stock. As holders exchange their Class B common shares for Class A common shares, our interest in Evolent Health LLC will increase. Therefore, shares of our Class B common stock are not considered dilutive shares for the purposes of calculating our diluted earnings (loss) per common share as related adjustment to net income (loss) available for common shareholders would equally offset the additional shares, resulting in the same earnings (loss) per common share. (3) For periods of net loss, shares used in the earnings (loss) per common share calculation represent basic shares as using diluted shares would be anti-dilutive. Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below: For the Three Months Ended March 31, 2019 2018 Exchangeable Class B common stock 3,190 2,141 Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs") 1,043 627 Stock options and performance-based stock options 1,966 2,162 Convertible senior notes 10,361 5,201 Total 16,560 10,131

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands): For the Three Months Ended March 31, 2019 2018 Award Type Stock options $ 1,360 $ 2,231 Performance-based stock options 110 110 RSUs 2,430 1,454 Performance-based RSUs 384 — LSUs 253 — Total $ 4,537 $ 3,795 Line Item Cost of revenue $ 791 $ 316 Selling, general and administrative expenses 3,746 3,479 Total $ 4,537 $ 3,795 No stock-based compensation in the totals above was capitalized as software development costs for the three months ended March 31, 2019 and 2018 , respectively. Stock-based awards were granted as follows (in thousands): For the Three Months Ended March 31, 2019 2018 Stock options 381 962 RSUs 501 753 LSUs 720 —

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year. The Company recorded $0.5 million in income tax benefit and less than $0.1 million in income tax expense for the three months ended March 31, 2019 and 2018 , respectively, which resulted in effective tax rates of 1.0% and less than (0.1)% , respectively. The income tax benefit recorded during the three months ended March 31, 2019 , primarily relates to the amortization of intangible assets acquired as part of the New Century Health transaction. Furthermore, Evolent Health, Inc. continues to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components as part of its outside basis difference in its partnership interest in Evolent Health LLC. As of December 31, 2018 , the Company had unrecognized tax benefits of $0.9 million that, if recognized, would not affect the effective tax rate. As of March 31, 2019 , there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year, with the exception of New Century Health’s examination by the State of California for 2015-2017. Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 9 above and “Part II - Item 8. Financial Statements and Supplementary Data - Note 12” in our 2018 Form 10-K for discussion of our TRA.

Investments In and Advances to

Investments In and Advances to Equity Method Investees	3 Months Ended
	Mar. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investments In and Advances to Equity Method Investees	Investments In and Advances to Equity Method Investees The Company has entered into joint venture agreements with various entities. As of March 31, 2019 and December 31, 2018 , the Company’s economic and voting interests in these entities ranged between 4% and 40% . The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities’ earnings and losses for each reporting period. The Company’s proportional share of the losses from these investments was approximately $0.4 million and $0.1 million for the three months ended March 31, 2019 and 2018 , respectively. The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenues related to these services agreements was $7.1 million and less than $0.1 million for the three months ended March 31, 2019 and 2018 , respectively.

Non-controlling Interests

Non-controlling Interests	3 Months Ended
	Mar. 31, 2019
Noncontrolling Interest [Abstract]
Non-controlling Interests	Non-controlling Interests As discussed in Note 1 , Evolent Health, Inc. does not own 100% of the economic interests of Evolent Health LLC. The Company’s ownership percentage changes with the issuance of Class A common stock and Class B Exchanges. Following is a description of events that resulted in changes to the Company’s ownership percentage during 2018 . There was no material change in the Company’s ownership percentage during the three months ended March 31, 2019 . The Company completed the March 2018 Private Sale during March 2018. The shares sold in the March 2018 Private Sale consisted of 1.2 million existing shares of the Company’s Class A common stock owned and held by The Advisory Board and 1.8 million newly-issued shares of the Company’s Class A common stock received by The Advisory Board pursuant to a Class B Exchange. As a result of this Class B Exchange and Evolent Health LLC’s cancellation of the Class B units during the March 2018 Private Sale, the Company’s economic interest in Evolent Health LLC increased from 96.6% to 98.9% immediately following the March 2018 Private Sale, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders’ equity attributable to Evolent Health, Inc. Also during the year ended December 31, 2018, the Company issued 3.1 million shares of Evolent Health LLC’s Class B common units and an equal number of the Company’s Class B common shares as part of the consideration for the New Century Health transaction. The Class B common units, together with a corresponding number of shares of the Company’s Class B common stock, can be exchanged for an equivalent number of shares of the Company’s Class A common stock. As a result of the Class B common units (and corresponding Class B common shares) issued as part of the New Century Health transaction, the Company’s economic interest in Evolent Health LLC decreased from 99.0% to 95.3% , immediately following the acquisition. In addition, the Company completed the November 2018 Private Sales during 2018. The shares sold in the November 2018 Private Sales consisted of 0.1 million existing shares of the Company’s Class A common stock owned by TPG and 0.7 million newly-issued shares of the Company’s Class A common stock received by TPG pursuant to Class B Exchanges. As a result of these Class B Exchanges and Evolent Health LLC’s cancellation of the Class B common units during the November 2018 Private Sales, the Company’s economic interest in Evolent Health LLC increased from 95.3% to 96.1% immediately following the November 2018 Private Sales. As of March 31, 2019 , and December 31, 2018 , we owned 96.1% of the economic interests in Evolent Health LLC. See Note 4 for further discussion of our business combinations and securities offerings. Changes in non-controlling interests (in thousands) for the periods presented were as follows: For the Three Months Ended March 31, 2019 2018 Non-controlling interests as of beginning-of-period $ 45,532 $ 35,427 Cumulative-effect adjustment from adoption of new accounting principle — 594 Decrease in non-controlling interests as a result of Class B Exchanges — (23,805 ) Amount attributable to NCI from 2019 business combination 6,500 — Net income (loss) attributable to non-controlling interests (1,910 ) (439 ) Reclassification of non-controlling interests (22 ) (5 ) Non-controlling interests as of end-of-period $ 50,100 $ 11,772

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: • Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; • Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and • Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. Recurring Fair Value Measurements In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): As of March 31, 2019 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 9,139 $ — $ — $ 9,139 Restricted cash and restricted investments (1) 34,774 — — 34,774 Total $ 43,913 $ — $ — $ 43,913 Liabilities Contingent consideration (2) — — 8,100 8,100 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 11,391 $ — $ — $ 11,391 Restricted cash and restricted investments (1) 31,226 — — 31,226 Total $ 42,617 $ — $ — $ 42,617 Liabilities Contingent consideration (2) — — 8,800 8,800 (1) Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of March 31, 2019 , and December 31, 2018 , as presented in the tables above. (2) Represents the contingent earn-out consideration related to the University Health Care, Inc. d/b/a Passport Health Plan (“Passport”) acquisition and the New Century Health transaction as described below. As of March 31, 2019 , $4.9 million was attributable to Passport and $3.2 million was attributable to New Century Health. As of December 31, 2018 , $5.6 million was attributable to Passport and $3.2 million was attributable to New Century Health. The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels for the three month periods ended March 31, 2019 and 2018 , respectively. In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks. The strategic alliance with Passport includes a provision for additional equity consideration contingent upon the Company obtaining new third-party Medicaid business in future periods. T he fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Passport contingent consideration are the five -year risk-adjusted recurring revenue compound annual growth rate (“CAGR”) and the applicable discount rate. A significant increase in the assumed five -year risk-adjusted recurring revenue CAGR projection or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration. The acquisition of New Century Health includes an earn-out of up to $11.4 million , contingent upon New Century Health achieving certain levels of operating results during 2019. The fair value of the earn-out was estimated based on the real options approach, a form of the income approach, which estimated the probability of New Century Health achieving certain levels of operating results during 2019. The significant unobservable inputs used in the fair value measurement of the New Century Health earn-out are the risk neutral probabilities that the 2019 operating results for New Century Health are sufficient to either exceed the minimum earn-out threshold or meet the earn-out target cap. A significant increase in either one of these metrics, in isolation, would result in a significantly higher fair value of the contingent consideration. Refer to Note 4 for additional discussion of the New Century Health transaction. The changes in our contingent consideration, measured at fair value, for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Three Months Ended March 31, 2019 2018 Balance as of beginning-of-period $ 8,800 $ 8,700 Settlements (800 ) — Realized and unrealized (gains) losses, net 100 100 Balance as of end-of-period $ 8,100 $ 8,800 The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: As of March 31, 2019 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Passport contingent consideration $ 4,900 Real options approach Risk-adjusted recurring revenue CAGR 103.9 % (1) Discount rate 5.5% - 6.5% New Century Health contingent consideration $ 3,200 Real options approach Risk-neutral probability exceeds threshold 39.0 % (2) Risk-neutral probability meets earn-out cap 24.0 % (2) As of December 31, 2018 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Passport contingent consideration $ 5,600 Real options approach Risk-adjusted recurring revenue CAGR 103.9 % (1) Discount rate 5.5% - 6.5% New Century Health contingent consideration $ 3,200 Real options approach Risk-neutral probability exceeds threshold 39.0 % (2) Risk-neutral probability meets earn-out cap 24.0 % (2) (1) The risk-adjusted recurring revenue CAGR is calculated over the five -year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rates is based on theoretical 2016 and 2017 recurring revenue of $1.0 million , resulting in a higher growth rate. The risk-adjusted recurring revenue CAGR from 2019-2021 is 61.8% . (2) These amounts represent 1) the probability that New Century Health will achieve at least the minimum level of operating results in 2019 to earn any contingent consideration ( 39.0% ) and 2) the probability that New Century Health will achieve 2019 operating results in excess of the maximum amount of contingent consideration payable ( 24.0% ). The risk-neutral probability rates were determined by projecting theoretical 2019 operating results using a simulation with one million trials. Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. See Notes 4 , 5 , 6 , 7 , 14 and 20 for further discussion of assets measured at fair value on a nonrecurring basis. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments. See Note 8 for information regarding the fair value of the 2025 Notes and the 2021 Notes.

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Parties	Related Parties The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements. As discussed in Note 14 , the Company has economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees’ earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. Revenues related to these services agreements was $7.1 million and less than $0.1 million for the three months ended March 31, 2019 and 2018 , respectively. The Company also works closely with UPMC, one of its founding investors. The Company’s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. We also conduct business with a company in which UPMC holds a significant equity interest. The following table presents revenues and expenses attributable to our related parties (in thousands): For the Three Months Ended March 31, 2019 2018 Revenue Transformation services $ 1,159 $ 32 Platform and operations services 12,944 7,291 Expenses Cost of revenue (exclusive of depreciation and amortization expenses) 7,830 3,190 Selling, general and administrative expenses 156 99

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting We define our reportable segments based on the way the chief operating decision maker (“CODM”), currently the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows: • Services, which consists of our technology-enabled value-based care services, specialty care management services and comprehensive health plan administration services; and • True Health, which consists of a commercial health plan we operate in New Mexico that focuses on small and large businesses. In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results. The CODM uses Adjusted EBITDA as the relevant segment performance measure to evaluate the performance of the segments and allocate resources. Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. Adjusted EBITDA is the sum of Services Adjusted EBITDA and True Health Adjusted EBITDA and is defined as EBITDA (net income (loss) attributable to Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses), adjusted to exclude changes in fair value of contingent consideration and indemnification assets, income (loss) from equity method investees, other income (expense), net, net (income) loss attributable to non-controlling interests, purchase accounting adjustments, stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, transaction costs related to acquisitions and business combinations and other one-time adjustments. When Adjusted EBITDA is discussed in this report, the most directly comparable GAAP financial measure is net income (loss) attributable to Evolent Health, Inc. Management considers Adjusted EBITDA to be the appropriate metric to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as it eliminates the effect of items which are not indicative of each segment's core operating performance. The following tables present our segment information (in thousands): Intersegment Services THNM Eliminations Consolidated Revenue Three Months Ended March 31, 2019 Services: Transformation services $ 3,353 $ — $ — $ 3,353 Platform and operations 150,351 — (3,059 ) 147,292 Services revenue 153,704 — (3,059 ) 150,645 True Health: Premiums — 47,376 (265 ) 47,111 Total revenue $ 153,704 $ 47,376 $ (3,324 ) $ 197,756 Three Months Ended March 31, 2018 Services: Transformation services $ 6,505 $ — $ — $ 6,505 Platform and operations 113,615 — (3,797 ) 109,818 Services revenue 120,120 — (3,797 ) 116,323 True Health: Premiums — 23,585 (194 ) 23,391 Total revenue $ 120,120 $ 23,585 $ (3,991 ) $ 139,714 Segments Services True Health Total Three Months Ended March 31, 2019 Adjusted EBITDA $ (15,499 ) $ 721 $ (14,778 ) Three Months Ended March 31, 2018 Adjusted EBITDA $ 6,966 $ 947 $ 7,913 The following table presents our reconciliation of segments total Adjusted EBITDA to net income (loss) attributable to Evolent Health, Inc. (in thousands): For the Three Months Ended March 31, 2019 2018 Net Income (Loss) Attributable to Evolent Health, Inc. $ (46,739 ) $ (13,626 ) Less: Interest income 1,060 1,072 Interest expense (3,562 ) (853 ) (Provision) benefit for income taxes 496 (3 ) Depreciation and amortization expenses (14,266 ) (9,496 ) Income (loss) from equity method investees (424 ) (131 ) Change in fair value of contingent consideration (100 ) (100 ) Other income (expense), net 427 (18 ) Net (income) loss attributable to non-controlling interests 1,910 439 ASC 606 transition adjustments — (4,498 ) Purchase accounting adjustments (596 ) (217 ) Stock-based compensation expense (4,537 ) (3,795 ) Severance costs (10,602 ) (1,594 ) Amortization of contract cost assets (754 ) (561 ) Transaction costs (1,013 ) (1,784 ) Adjusted EBITDA $ (14,778 ) $ 7,913 Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.

Reserves for Claims and Perform

Reserves for Claims and Performance-Based Arrangements	3 Months Ended
	Mar. 31, 2019
Insurance [Abstract]
Reserves for Claims and Performance-Based Arrangements	Reserves for Claims and Performance-Based Arrangements The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its specialty care management services. The Company also maintains reserves for claims incurred but not paid related to its capitation arrangement and for its health plan, True Health, in New Mexico. Reserves for claims and performance-based arrangements reflect estimates of the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed to NMHC under the Reinsurance Agreement, as discussed further in Note 9 . The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability, for reserves related to its specialty care management services and True Health, is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership and 4) the mix of products. The Company’s policy, for reserves related to its specialty care management services and True Health, is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. For more recent months, the Company expects to rely more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends. For reserves related to the Company’s capitation arrangement, the liability is calculated based on the budgeted medical loss ratio as historical data and completion patterns are not credible. Activity in reserves for claims and performance-based arrangements was as follows (in thousands): For the Three Months Ended March 31, 2019 2018 Services (1) True Health Consolidated Services (1) True Health Consolidated Beginning balance $ 17,715 $ 9,880 $ 27,595 $ — $ — $ — Incurred costs related to: Current year 33,777 31,498 65,275 — 16,749 16,749 Prior years 6,879 6,259 13,138 — — — Total incurred 40,656 37,757 78,413 — 16,749 16,749 Paid costs related to: Current year 28,684 11,682 40,366 — 10,050 10,050 Prior years 6,871 7,156 14,027 — — — Total paid 35,555 18,838 54,393 — 10,050 10,050 Other adjustments (2) (438 ) (21,158 ) (21,596 ) — — — Change during the year 4,663 (2,239 ) 2,424 — 6,699 6,699 Ending balance $ 22,378 $ 7,641 $ 30,019 $ — $ 6,699 $ 6,699 (1) Costs related the Company’s capitation arrangement as well as costs incurred to provide specialty care management services are recorded within cost of revenue in our consolidated statements of operations and comprehensive income (loss). (2) Other adjustments to reserves for claims and performance-based arrangements for Services reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf. Other adjustments related to the True Health segment represent premiums received less administrative expenses related to the Reinsurance Agreement. Refer to Note 9 for additional information about the Reinsurance Agreement.

Investments

Investments	3 Months Ended
	Mar. 31, 2019
Investments [Abstract]
Investments	Investments Our investments are classified as held-to-maturity as we have both the intent and ability to hold the investments until their individual maturities. The amortized cost, gross unrealized gains and losses, and fair value of our investments as measured using Level 2 inputs as of the periods indicated below (in thousands) were as follows: As of March 31, 2019 Gross Gross Amortized Unrealized Unrealized Fair Cost Gains Losses Value U.S. Treasury bills $ 10,388 $ 211 $ — $ 10,599 Corporate bonds 1,090 37 — 1,127 Other CMOs 1,715 21 — 1,736 Yankees 596 23 — 619 Total investments $ 13,789 $ 292 $ — $ 14,081 As of December 31, 2018 Gross Gross Amortized Unrealized Unrealized Fair Cost Gains Losses Value U.S. Treasury bills $ 7,982 $ 120 $ — $ 8,102 Corporate bonds 887 17 — 904 Other CMOs 545 6 — 551 Yankees 596 11 — 607 Total investments $ 10,010 $ 154 $ — $ 10,164 The amortized cost and fair value of our investments by contractual maturities as of the periods indicated below (in thousands) were as follows: As of March 31, 2019 As of December 31, 2018 Amortized Fair Amortized Fair Cost Value Cost Value Due in one year or less $ 2,046 $ 2,050 $ — $ — Due after one year through five years 11,743 12,031 9,666 9,813 Due after five years through ten years — — 344 351 Total $ 13,789 $ 14,081 $ 10,010 $ 10,164 When a held-to-maturity investment is in an unrealized loss position, we assess whether or not we expect to recover the entire cost basis of security, based on our best estimate of the present value of cash flows expected to be collected from the debt security. Factors considered in our analysis include the reasons for the unrealized loss position, the severity and duration of the unrealized loss position, credit worthiness and forecasted performance of the investee. In cases where the estimated present value of future cash flows is less than our cost basis, we recognize an other than temporary impairment and write the investment down to its fair value. The new cost basis would not be changed for subsequent recoveries in fair value. We did not hold any securities that were in an unrealized loss position as of March 31, 2019 or December 31, 2018 .

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information The following represents supplemental disclosure of cash flow information and non-cash investing and financing activities (in thousands): For the Three Months Ended March 31, 2019 2018 Supplemental disclosure of cash flow information Operating cash flows from operating leases $ 4,165 $ — Leased assets obtained in exchange for new finance lease liabilities 14,917 — Non-cash investing and financing activities Accrued property and equipment purchases $ 487 $ 3,183 Class A common stock issued for payment of Passport earn-out 800 — Consideration for asset acquisitions or business combinations — 500 Settlement of escrow related to asset acquisition — 2,519 Effects of Class B Exchanges Decrease in non-controlling interests as a result of Class B Exchanges — 23,805 Decrease in deferred tax liability as a result of securities offerings — 908

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2018 , has been derived from audited financial statements as of that date. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (“GAAP”) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (“SEC”). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2018 Form 10-K.
Accounting Estimates and Assumptions	Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles and long-lived assets), liabilities (including IBNR), consideration related to business combinations and asset acquisitions, revenue recognition including variable consideration, estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, contingent payments, allowance for doubtful accounts, depreciable lives of assets, impairment of long lived assets (including equity method investments), stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, valuation of intangible assets (including goodwill), purchase price allocation in taxable stock transactions and the useful lives of intangible assets.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation.
Operating Segments	Operating Segments Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company operates through two segments: (1) Services, and (2) True Health. Our Services segment consists of our technology-enabled value-based care services, specialty care management services and comprehensive health plan administration services. Our True Health segment consists of a commercial health plan we operate in New Mexico that focuses on small and large businesses. See Note 18 for a discussion of our operating results by segment.
Revenue Recognition	Revenue Recognition Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan strategy. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management (through performance-based arrangements) and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily third-party administration (“TPA”) services. Revenue is recognized when control of the services is transferred to our customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition for our Services segment from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. True Health also derives revenue from reinsurance premiums assumed from NMHC under the terms of the Reinsurance Agreement (as defined in Note 9 ). The portion of premiums that will be earned in the future or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as short-term deferred revenue on our consolidated balance sheets. See Note 5 for further discussion of our policies related to revenue recognition.
Leases	Leases As discussed in Note 3 , we adopted Accounting Standards Update (“ASU”) 2016-02 effective January 1, 2019. The following reflects our updated policy for leases. The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on the balance sheet. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is offset against rent expense over the terms of the respective leases. Refer to Note 10 for additional lease disclosures.
Restricted Cash and Restricted Investments	Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations
Business Combinations	Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.
Goodwill	Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level, which is consistent with the way management evaluates our business. The Company has three reporting units: Legacy Services, New Century Health and True Health. Our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that would more likely than not reduce the fair value of a reporting unit below its carrying amount.
Intangible Assets, Net	Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. Information regarding the determination and allocation of the fair value of recently acquired assets and liabilities is further described within Note 4 . The following summarizes the estimated useful lives by asset classification: Corporate trade name 10-20 years Customer relationships 10-25 years Technology 5 years Provider network contracts 5 years Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 7 for additional discussion regarding our intangible assets.
Reserves for Claims and Performance-based Arrangements	Reserves for claims and performance-based arrangements Reserves for claims and performance-based arrangements for our Services and True Health segments reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed to NMHC under a reinsurance agreement as discussed further in Note 9 . The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 19 for additional discussion regarding our reserves for claims and performance-based arrangements.
Foreign Currency	Foreign Currency The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity.
Adoption of New Accounting Standards and Future Adoption of New Accounting Standards	Adoption of New Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases , in order to establish the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This update introduces a new standard on accounting for leases, including a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in ASC 606. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, which is intended to make targeted improvements to ASU 2016-02. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard using an effective date method rather than the earliest comparative period. The requirements of ASU 2018-11 are effective on the same date as the requirements of ASU 2016-02. We adopted ASU 2016-02 as of January 1, 2019, using the modified retrospective approach. Further, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of additional right-of-use assets and lease liabilities of approximately $51.4 million and $47.4 million , respectively, on our consolidated balance sheet as of January 1, 2019. The standard had no impact on our results of operations. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Services Contract . The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted the requirements of ASU 2018-15 effective January 1, 2019. There was no impact to our consolidated balance sheets or results of operations as of or for the three months ended March 31, 2019 . In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers , in order to clarify the principles of recognizing revenue. This standard establishes the core principle of recognizing revenue to depict the transfer of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB defines a five-step process that systematically identifies the various components of the revenue recognition process, culminating with the recognition of revenue upon satisfaction of an entity’s performance obligations. By completing all five steps of the process, the core principles of revenue recognition will be achieved. The new revenue standard (including updates) is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016. The guidance permits two methods of adoption: i) the full retrospective method applying the standard to each prior reporting period presented, or ii) the modified retrospective method with a cumulative effect of initially applying the guidance recognized at the date of initial application. The standard also allows entities to apply certain practical expedients at their discretion. The Company adopted the standard effective January 1, 2018, using the modified retrospective method for only contracts that were not completed at the date of initial application. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (“ASC 605”). The adoption of this standard resulted in changes related to revenue recognition for contracts that contain certain features, such as variable consideration. These changes generally accelerate revenue recognition. In addition, certain customer setup costs, which have historically been expensed as incurred, will now be capitalized. Evolent recognized the cumulative effect of applying the new revenue standard as a $17.3 million adjustment to the opening balance of retained earnings, including non-controlling interests, in the first quarter of 2018, primarily as a result of capitalization of expenses related to contract acquisition and fulfillment costs and acceleration of revenue due to variable consideration estimation. See Note 5 for additional disclosures regarding Evolent's contracts with customers. See Note 2 for updated revenue recognition accounting policy. Future Adoption of New Accounting Standards In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments . With respect to assets measured at amortized cost, such as held-to-maturity assets, the update requires presentation of the amortized cost net of a credit loss allowance. The update eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity’s current estimate of all future expected credit losses as opposed to the previous standard, when an entity only considered past events and current conditions. With respect to available for sale debt securities, the update requires that credit losses be presented as an allowance rather than as a write-down. The update is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We intend to adopt the requirements of this standard effective January 1, 2020, and are currently evaluating the impact of the adoption on our financial condition and results of operations.
Nonrecurring Fair Value Measurements and Other Fair Value Disclosures	Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. See Notes 4 , 5 , 6 , 7 , 14 and 20 for further discussion of assets measured at fair value on a nonrecurring basis. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments. See Note 8 for information regarding the fair value of the 2025 Notes and the 2021 Notes.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of restricted cash and cash equivalents	Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: As of As of March 31, December 31, 2019 2018 Collateral for letters of credit for facility leases (1) $ 3,710 $ 3,710 Collateral with financial institutions (2) 37,691 34,142 Claims processing services (3) 14,939 122,439 Other 1,616 532 Total restricted cash and restricted investments 57,956 160,823 Current restricted investments 711 211 Current restricted cash 50,209 154,507 Total current restricted cash and restricted investments 50,920 154,718 Noncurrent restricted investments 608 607 Noncurrent restricted cash 6,428 5,498 Total noncurrent restricted cash and restricted investments $ 7,036 $ 6,105 (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 9 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements. As of March 31, 2019 , and December 31, 2018 , approximately $34.8 million and $31.2 million of the collateral amount was in a trust account and invested in a money market fund. The amounts invested in money market funds are considered restricted cash and are carried at fair value, which approximates cost. See Note 16 for discussion of our fair value measurement and Note 9 for discussion of our risk-sharing arrangements. As of March 31, 2019 , and December 31, 2018 , approximately $2.9 million of the collateral amount was held in FDIC participating bank accounts, primarily related to a line of credit. (3) Represents cash held by Evolent related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. As of March 31, 2019 2018 Cash and cash equivalents $ 170,817 $ 200,316 Restricted cash and restricted investments 57,956 36,757 Restricted investments included in restricted cash and restricted investments (1,319 ) (711 ) Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 227,454 $ 236,362
Schedule of intangible assets	The following summarizes the estimated useful lives by asset classification: Corporate trade name 10-20 years Customer relationships 10-25 years Technology 5 years Provider network contracts 5 years Details of our intangible assets (in thousands) are presented below: As of March 31, 2019 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 14.9 $ 23,300 $ 3,856 $ 19,444 Customer relationships 17.6 291,519 32,818 258,701 Technology 2.7 82,922 36,261 46,661 Below market lease, net 3.8 4,097 3,037 1,060 Provider network contracts 4.4 11,900 1,535 10,365 Total $ 413,738 $ 77,507 $ 336,231 As of December 31, 2018 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 15.2 $ 23,300 $ 3,511 $ 19,789 Customer relationships 18.1 281,219 29,184 252,035 Technology 3.0 82,922 31,764 51,158 Below market lease, net 4.0 4,097 3,003 1,094 Provider network contracts 4.6 11,900 940 10,960 Total $ 403,438 $ 68,402 $ 335,036

Transactions (Tables)

Transactions (Tables)	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Schedule of allocation of purchase price	The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2018 , as follows (in thousands): Purchase consideration: Cash $ 124,652 Fair value of Class B common stock issued 83,173 Fair value of contingent consideration 3,200 Total consideration $ 211,025 Tangible assets acquired: Cash and cash equivalents $ 5,963 Accounts receivable 5,559 Prepaid expenses and other current assets 7,901 Property and equipment 381 Other noncurrent assets 148 Identifiable intangible assets acquired: Customer relationships 72,500 Technology 27,000 Corporate trade name 4,300 Provider network contracts 9,600 Liabilities assumed: Accounts payable 1,167 Accrued liabilities 1,494 Accrued compensation and employee benefits 3,966 Reserves for claims and performance-based arrangements 18,631 Deferred tax liabilities 24,041 Other long-term liabilities 6,138 Goodwill 133,110 Net assets acquired $ 211,025
Schedule of net assets acquired	The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of January 2, 2018 , as follows (in thousands): Purchase consideration Cash paid to NMHC $ 10,000 Cash paid to escrow agent 252 Total consideration $ 10,252 Identifiable intangible assets acquired and liabilities assumed Customer relationships $ 2,700 Provider network contracts 2,300 Above market lease (100 ) Accrued compensation and employee benefits (474 ) Goodwill 5,826 Net assets acquired $ 10,252
Business acquisition, pro forma information	The pro forma adjustments are based on available information and assumptions that the Company believes are reasonable to reflect the impact of these transactions on the Company’s historical financial information on a pro forma basis (in thousands, except per share data). For the Three Months Ended March 31, 2019 2018 Revenue $ 197,756 $ 184,630 Net income (loss) (48,649 ) (14,885 ) Net income (loss) attributable to non-controlling interests (1,881 ) (972 ) Net income (loss) attributable to Evolent Health, Inc. (46,768 ) (13,913 ) Net income (loss) per Common Share available to common shareholders Basic and Diluted $ (0.59 ) $ (0.18 )

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	The following table represents Evolent’s Services segment revenue disaggregated by revenue type (in thousands), excluding revenues from our True Health segment and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, Financial Services-Insurance . For the Three Months Ended March 31, 2019 2018 Services Revenue Transformation services $ 3,353 $ 6,505 Platform and operations services 147,292 108,420
Contract with customer, asset and liability	The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): As of As of March 31, December 31, 2019 2018 Short-term receivables (1) $ 63,886 $ 78,380 Long-term receivables (1) 6,550 6,550 Short-term contract assets 1,282 2,102 Long-term contract assets 1,695 961 Short-term deferred revenue 22,320 20,584 Long-term deferred revenue 443 1,502 (1) Excludes pharmacy claims receivable and premiums receivable Changes in contract assets and deferred revenue for the three months ended March 31, 2019 , were as follows (in thousands): Contract assets Balance as of beginning-of-period $ 3,063 Reclass to receivables, as the right to consideration becomes unconditional (1,183 ) Contract assets recognized, net of reclass to receivables 1,097 Balance as of end-of-period $ 2,977 Deferred revenue Balance as of beginning-of-period $ 22,086 Reclass to revenue, as a result of performance obligations satisfied (11,807 ) Cash received in advance of satisfaction of performance obligations 12,484 Balance as of end-of-period $ 22,763

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Summary of property and equipment	The following summarizes our property and equipment (in thousands): As of As of March 31, December 31, 2019 2018 Computer hardware $ 10,850 $ 10,421 Furniture and equipment 3,226 3,187 Internal-use software development costs 90,284 81,640 Leasehold improvements 10,011 10,118 Total property and equipment 114,371 105,366 Accumulated depreciation and amortization (36,992 ) (31,738 ) Total property and equipment, net $ 77,379 $ 73,628

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The following tables summarize the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands): For the Three Months Ended March 31, 2019 Services True Health Consolidated Balance as of beginning-of-period (1) $ 762,419 $ 5,705 $ 768,124 Goodwill Acquired 2,200 — 2,200 Measurement period adjustments — — — Foreign currency translation 10 — 10 Balance as of end-of-period $ 764,629 $ 5,705 $ 770,334 (1) Net of cumulative inception to date impairment of $160.6 million . For the Year Ended December 31, 2018 Services True Health Consolidated Balance as of beginning-of-period (1) $ 628,186 $ — $ 628,186 Goodwill Acquired (2) 134,343 5,826 140,169 Measurement period adjustments (3) 4 (121 ) (117 ) Foreign currency translation (4) (114 ) — (114 ) Balance as of end-of-period $ 762,419 $ 5,705 $ 768,124 (1) Net of cumulative inception to date impairment of $160.6 million . (2) Goodwill acquired primarily as a result of the New Century Health and True Health transactions, as discussed in Note 4 . (3) Measurement period adjustments related to transactions completed during the first quarter of 2018. (4) Foreign currency translation related to a transaction completed during the first quarter of 2018.
Schedule of intangible assets	The following summarizes the estimated useful lives by asset classification: Corporate trade name 10-20 years Customer relationships 10-25 years Technology 5 years Provider network contracts 5 years Details of our intangible assets (in thousands) are presented below: As of March 31, 2019 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 14.9 $ 23,300 $ 3,856 $ 19,444 Customer relationships 17.6 291,519 32,818 258,701 Technology 2.7 82,922 36,261 46,661 Below market lease, net 3.8 4,097 3,037 1,060 Provider network contracts 4.4 11,900 1,535 10,365 Total $ 413,738 $ 77,507 $ 336,231 As of December 31, 2018 Weighted- Average Gross Net Remaining Carrying Accumulated Carrying Useful Life Amount Amortization Value Corporate trade name 15.2 $ 23,300 $ 3,511 $ 19,789 Customer relationships 18.1 281,219 29,184 252,035 Technology 3.0 82,922 31,764 51,158 Below market lease, net 4.0 4,097 3,003 1,094 Provider network contracts 4.6 11,900 940 10,960 Total $ 403,438 $ 68,402 $ 335,036
Schedule of future estimated amortization of intangible assets	Future estimated amortization of intangible assets (in thousands) as of March 31, 2019 , is as follows: 2019 $ 28,419 2020 33,309 2021 29,173 2022 25,292 2023 22,528 Thereafter 197,510 Total $ 336,231

Long-term Debt (Tables)

Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of convertible debt	The following table summarizes the carrying value of the long-term debt (in thousands): As of As of March 31, December 31, 2019 2018 2025 Notes Carrying value $ 100,779 $ 98,730 Unamortized debt discount and issuance costs allocated to debt 71,721 73,770 Principal amount $ 172,500 $ 172,500 Remaining amortization period (years) 6.5 6.8 2021 Notes Carrying value $ 122,541 $ 122,311 Unamortized issuance costs 2,459 2,689 Principal amount $ 125,000 $ 125,000 Remaining amortization period (years) 2.7 2.9

Commitments and Contingencies

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Summary of premiums and claims assumed under the Reinsurance Agreement	The following table summarizes premiums and claims assumed under the Reinsurance Agreement for the three months ended March 31, 2019 (in thousands): Reinsurance premiums assumed $ 25,441 Claims assumed 21,151 Claims-related administrative expenses 4,282 (Increase) decrease in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement 8 Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period 1,243 Reinsurance payments 1,243 Receivables for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period $ 8
Summary of major partners	The following table summarizes those partners who represented at least 10.0% of our trade accounts receivable for the periods presented: As of As of March 31, December 31, 2019 2018 Customer C 15.4 % 23.3 % The following table summarizes those partners who represented at least 10.0% of our revenue for the periods presented: For the Three Months Ended March 31, 2019 2018 Customer A 14.0 % * Customer B 13.1 % 20.1 % Customer C * 10.6 % * Represents less than 10.0% of the respective balance

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms	The following table summarizes the components of our lease expense (in thousands): For the Three Months Ended March 31, 2019 Operating lease cost $ 3,281 Variable lease cost 1,455 Total lease cost $ 4,736 Our weighted-average discount rate and our weighted-remaining lease terms (in years) is as follows: As of March 31, 2019 Weighted average discount rate 6.25 % Weighted average remaining lease term 9.71
Schedule of maturity of lease liabilities	Maturity of lease liabilities (in thousands) as of March 31, 2019 , is as follows: Operating lease expense (1) 2019 $ 5,226 2020 8,613 2021 8,719 2022 7,563 2023 7,414 2024 and thereafter 47,118 Total lease payments 84,653 Less: Interest 24,017 Present value of lease liabilities 60,636 (1) We have additional operating lease agreements for office space that have not yet commenced as of March 31, 2019 . The minimum lease payments for those leases are $31.1 million and the leases will commence throughout the remainder of 2019.

Earnings (Loss) Per Common Sh_2

Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Computation of basic and diluted earnings per share	The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Three Months Ended March 31, 2019 2018 Net income (loss) $ (48,649 ) $ (14,065 ) Less: Net income (loss) attributable to non-controlling interests (1,910 ) (439 ) Net income (loss) available for common shareholders (1) (2) $ (46,739 ) $ (13,626 ) Weighted-average common shares outstanding (2) (3) 79,335 75,375 Earnings (Loss) per Common Share Basic $ (0.59 ) $ (0.18 ) Diluted (0.59 ) (0.18 ) (1) For periods of net loss, net income (loss) available for common shareholders is the same for both basic and diluted purposes. (2) Each Class B common unit of Evolent Health LLC can be exchanged (together with a corresponding number of shares of our Class B common stock) for one share of our Class A common stock. As holders exchange their Class B common shares for Class A common shares, our interest in Evolent Health LLC will increase. Therefore, shares of our Class B common stock are not considered dilutive shares for the purposes of calculating our diluted earnings (loss) per common share as related adjustment to net income (loss) available for common shareholders would equally offset the additional shares, resulting in the same earnings (loss) per common share. (3) For periods of net loss, shares used in the earnings (loss) per common share calculation represent basic shares as using diluted shares would be anti-dilutive.
Schedule of antidilutive securities excluded from computation of earnings per share	Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below: For the Three Months Ended March 31, 2019 2018 Exchangeable Class B common stock 3,190 2,141 Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs") 1,043 627 Stock options and performance-based stock options 1,966 2,162 Convertible senior notes 10,361 5,201 Total 16,560 10,131

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation expense	Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands): For the Three Months Ended March 31, 2019 2018 Award Type Stock options $ 1,360 $ 2,231 Performance-based stock options 110 110 RSUs 2,430 1,454 Performance-based RSUs 384 — LSUs 253 — Total $ 4,537 $ 3,795 Line Item Cost of revenue $ 791 $ 316 Selling, general and administrative expenses 3,746 3,479 Total $ 4,537 $ 3,795
Stock-based awards granted	Stock-based awards were granted as follows (in thousands): For the Three Months Ended March 31, 2019 2018 Stock options 381 962 RSUs 501 753 LSUs 720 —

Non-controlling Interests (Tabl

Non-controlling Interests (Tables)	3 Months Ended
	Mar. 31, 2019
Noncontrolling Interest [Abstract]
Schedule of changes in non-controlling interests	Changes in non-controlling interests (in thousands) for the periods presented were as follows: For the Three Months Ended March 31, 2019 2018 Non-controlling interests as of beginning-of-period $ 45,532 $ 35,427 Cumulative-effect adjustment from adoption of new accounting principle — 594 Decrease in non-controlling interests as a result of Class B Exchanges — (23,805 ) Amount attributable to NCI from 2019 business combination 6,500 — Net income (loss) attributable to non-controlling interests (1,910 ) (439 ) Reclassification of non-controlling interests (22 ) (5 ) Non-controlling interests as of end-of-period $ 50,100 $ 11,772

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Summary of assets at fair value on recurring basis	The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): As of March 31, 2019 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 9,139 $ — $ — $ 9,139 Restricted cash and restricted investments (1) 34,774 — — 34,774 Total $ 43,913 $ — $ — $ 43,913 Liabilities Contingent consideration (2) — — 8,100 8,100 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 11,391 $ — $ — $ 11,391 Restricted cash and restricted investments (1) 31,226 — — 31,226 Total $ 42,617 $ — $ — $ 42,617 Liabilities Contingent consideration (2) — — 8,800 8,800 (1) Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of March 31, 2019 , and December 31, 2018 , as presented in the tables above. (2) Represents the contingent earn-out consideration related to the University Health Care, Inc. d/b/a Passport Health Plan (“Passport”) acquisition and the New Century Health transaction as described below. As of March 31, 2019 , $4.9 million was attributable to Passport and $3.2 million was attributable to New Century Health. As of December 31, 2018 , $5.6 million was attributable to Passport and $3.2 million was attributable to New Century Health.
Summary of liabilities at fair value on recurring basis	The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): As of March 31, 2019 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 9,139 $ — $ — $ 9,139 Restricted cash and restricted investments (1) 34,774 — — 34,774 Total $ 43,913 $ — $ — $ 43,913 Liabilities Contingent consideration (2) — — 8,100 8,100 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents (1) $ 11,391 $ — $ — $ 11,391 Restricted cash and restricted investments (1) 31,226 — — 31,226 Total $ 42,617 $ — $ — $ 42,617 Liabilities Contingent consideration (2) — — 8,800 8,800 (1) Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of March 31, 2019 , and December 31, 2018 , as presented in the tables above. (2) Represents the contingent earn-out consideration related to the University Health Care, Inc. d/b/a Passport Health Plan (“Passport”) acquisition and the New Century Health transaction as described below. As of March 31, 2019 , $4.9 million was attributable to Passport and $3.2 million was attributable to New Century Health. As of December 31, 2018 , $5.6 million was attributable to Passport and $3.2 million was attributable to New Century Health.
Changes in contingent consideration measured at fair value	The changes in our contingent consideration, measured at fair value, for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Three Months Ended March 31, 2019 2018 Balance as of beginning-of-period $ 8,800 $ 8,700 Settlements (800 ) — Realized and unrealized (gains) losses, net 100 100 Balance as of end-of-period $ 8,100 $ 8,800
Valuation techniques and significant unobservable inputs of Level 3 fair value measurements	The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: As of March 31, 2019 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Passport contingent consideration $ 4,900 Real options approach Risk-adjusted recurring revenue CAGR 103.9 % (1) Discount rate 5.5% - 6.5% New Century Health contingent consideration $ 3,200 Real options approach Risk-neutral probability exceeds threshold 39.0 % (2) Risk-neutral probability meets earn-out cap 24.0 % (2) As of December 31, 2018 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Passport contingent consideration $ 5,600 Real options approach Risk-adjusted recurring revenue CAGR 103.9 % (1) Discount rate 5.5% - 6.5% New Century Health contingent consideration $ 3,200 Real options approach Risk-neutral probability exceeds threshold 39.0 % (2) Risk-neutral probability meets earn-out cap 24.0 % (2) (1) The risk-adjusted recurring revenue CAGR is calculated over the five -year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rates is based on theoretical 2016 and 2017 recurring revenue of $1.0 million , resulting in a higher growth rate. The risk-adjusted recurring revenue CAGR from 2019-2021 is 61.8% . (2) These amounts represent 1) the probability that New Century Health will achieve at least the minimum level of operating results in 2019 to earn any contingent consideration ( 39.0% ) and 2) the probability that New Century Health will achieve 2019 operating results in excess of the maximum amount of contingent consideration payable ( 24.0% ). The risk-neutral probability rates were determined by projecting theoretical 2019 operating results using a simulation with one million trials.

Related Parties (Tables)

Related Parties (Tables)	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Revenues and expenses related to affiliates	The following table presents revenues and expenses attributable to our related parties (in thousands): For the Three Months Ended March 31, 2019 2018 Revenue Transformation services $ 1,159 $ 32 Platform and operations services 12,944 7,291 Expenses Cost of revenue (exclusive of depreciation and amortization expenses) 7,830 3,190 Selling, general and administrative expenses 156 99

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Reconciliation of revenue from segments to consolidated	The following tables present our segment information (in thousands): Intersegment Services THNM Eliminations Consolidated Revenue Three Months Ended March 31, 2019 Services: Transformation services $ 3,353 $ — $ — $ 3,353 Platform and operations 150,351 — (3,059 ) 147,292 Services revenue 153,704 — (3,059 ) 150,645 True Health: Premiums — 47,376 (265 ) 47,111 Total revenue $ 153,704 $ 47,376 $ (3,324 ) $ 197,756 Three Months Ended March 31, 2018 Services: Transformation services $ 6,505 $ — $ — $ 6,505 Platform and operations 113,615 — (3,797 ) 109,818 Services revenue 120,120 — (3,797 ) 116,323 True Health: Premiums — 23,585 (194 ) 23,391 Total revenue $ 120,120 $ 23,585 $ (3,991 ) $ 139,714 Segments Services True Health Total Three Months Ended March 31, 2019 Adjusted EBITDA $ (15,499 ) $ 721 $ (14,778 ) Three Months Ended March 31, 2018 Adjusted EBITDA $ 6,966 $ 947 $ 7,913
Reconciliation of Adjusted EBITDA to net income (loss)	The following table presents our reconciliation of segments total Adjusted EBITDA to net income (loss) attributable to Evolent Health, Inc. (in thousands): For the Three Months Ended March 31, 2019 2018 Net Income (Loss) Attributable to Evolent Health, Inc. $ (46,739 ) $ (13,626 ) Less: Interest income 1,060 1,072 Interest expense (3,562 ) (853 ) (Provision) benefit for income taxes 496 (3 ) Depreciation and amortization expenses (14,266 ) (9,496 ) Income (loss) from equity method investees (424 ) (131 ) Change in fair value of contingent consideration (100 ) (100 ) Other income (expense), net 427 (18 ) Net (income) loss attributable to non-controlling interests 1,910 439 ASC 606 transition adjustments — (4,498 ) Purchase accounting adjustments (596 ) (217 ) Stock-based compensation expense (4,537 ) (3,795 ) Severance costs (10,602 ) (1,594 ) Amortization of contract cost assets (754 ) (561 ) Transaction costs (1,013 ) (1,784 ) Adjusted EBITDA $ (14,778 ) $ 7,913

Reserves for Claims and Perfo_2

Reserves for Claims and Performance-Based Arrangements (Tables)	3 Months Ended
	Mar. 31, 2019
Insurance [Abstract]
Activity in claims reserves	Activity in reserves for claims and performance-based arrangements was as follows (in thousands): For the Three Months Ended March 31, 2019 2018 Services (1) True Health Consolidated Services (1) True Health Consolidated Beginning balance $ 17,715 $ 9,880 $ 27,595 $ — $ — $ — Incurred costs related to: Current year 33,777 31,498 65,275 — 16,749 16,749 Prior years 6,879 6,259 13,138 — — — Total incurred 40,656 37,757 78,413 — 16,749 16,749 Paid costs related to: Current year 28,684 11,682 40,366 — 10,050 10,050 Prior years 6,871 7,156 14,027 — — — Total paid 35,555 18,838 54,393 — 10,050 10,050 Other adjustments (2) (438 ) (21,158 ) (21,596 ) — — — Change during the year 4,663 (2,239 ) 2,424 — 6,699 6,699 Ending balance $ 22,378 $ 7,641 $ 30,019 $ — $ 6,699 $ 6,699 (1) Costs related the Company’s capitation arrangement as well as costs incurred to provide specialty care management services are recorded within cost of revenue in our consolidated statements of operations and comprehensive income (loss). (2) Other adjustments to reserves for claims and performance-based arrangements for Services reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf. Other adjustments related to the True Health segment represent premiums received less administrative expenses related to the Reinsurance Agreement. Refer to Note 9 for additional information about the Reinsurance Agreement.

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2019
Investments [Abstract]
Summary investment holdings	The amortized cost, gross unrealized gains and losses, and fair value of our investments as measured using Level 2 inputs as of the periods indicated below (in thousands) were as follows: As of March 31, 2019 Gross Gross Amortized Unrealized Unrealized Fair Cost Gains Losses Value U.S. Treasury bills $ 10,388 $ 211 $ — $ 10,599 Corporate bonds 1,090 37 — 1,127 Other CMOs 1,715 21 — 1,736 Yankees 596 23 — 619 Total investments $ 13,789 $ 292 $ — $ 14,081 As of December 31, 2018 Gross Gross Amortized Unrealized Unrealized Fair Cost Gains Losses Value U.S. Treasury bills $ 7,982 $ 120 $ — $ 8,102 Corporate bonds 887 17 — 904 Other CMOs 545 6 — 551 Yankees 596 11 — 607 Total investments $ 10,010 $ 154 $ — $ 10,164
Investments classified by contractual maturity date	The amortized cost and fair value of our investments by contractual maturities as of the periods indicated below (in thousands) were as follows: As of March 31, 2019 As of December 31, 2018 Amortized Fair Amortized Fair Cost Value Cost Value Due in one year or less $ 2,046 $ 2,050 $ — $ — Due after one year through five years 11,743 12,031 9,666 9,813 Due after five years through ten years — — 344 351 Total $ 13,789 $ 14,081 $ 10,010 $ 10,164

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Supplemental cash flow information	The following represents supplemental disclosure of cash flow information and non-cash investing and financing activities (in thousands): For the Three Months Ended March 31, 2019 2018 Supplemental disclosure of cash flow information Operating cash flows from operating leases $ 4,165 $ — Leased assets obtained in exchange for new finance lease liabilities 14,917 — Non-cash investing and financing activities Accrued property and equipment purchases $ 487 $ 3,183 Class A common stock issued for payment of Passport earn-out 800 — Consideration for asset acquisitions or business combinations — 500 Settlement of escrow related to asset acquisition — 2,519 Effects of Class B Exchanges Decrease in non-controlling interests as a result of Class B Exchanges — 23,805 Decrease in deferred tax liability as a result of securities offerings — 908

Organization (Details)

Organization (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)segment	Dec. 31, 2018USD ($)	Nov. 30, 2018	Oct. 31, 2018	Oct. 01, 2018	Sep. 30, 2018	Mar. 31, 2018USD ($)	Aug. 31, 2017
Organization [Line Items]
Number of reportable segments | segment	2
Cash and cash equivalents | $	$ 170,817	$ 228,320					$ 200,316
Evolent Health LLC
Organization [Line Items]
Parent's ownership percentage	96.10%		96.10%	95.30%	95.30%	99.00%	98.90%	96.60%
Evolent Health LLC | Pre-Organization Members
Organization [Line Items]
Evolent Health LLC ownership interest	100.00%

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Operating Segments (Details)	3 Months Ended
	Mar. 31, 2019segment
Accounting Policies [Abstract]
Number of reportable segments	2

Basis of Presentation, Summar_5

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	$ 57,956	$ 160,823	$ 36,757
Current restricted investments	711	211
Current restricted cash	50,209	154,507
Total current restricted cash and restricted investments	50,920	154,718
Noncurrent restricted investments	608	607
Noncurrent restricted cash	6,428	5,498
Total non-current restricted cash and restricted investments	7,036	6,105
Cash and cash equivalents	170,817	228,320	200,316
Restricted investments included in restricted cash and restricted investments	(1,319)		$ (711)
Collateral for letters of credit for facility leases
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	3,710	3,710
Claims processing services
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	14,939	122,439
Other
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	1,616	532
Collateral with financial institutions, money market fund
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	34,800	31,200
FDIC participating bank account
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments	$ 2,900	$ 2,900

Basis of Presentation, Summar_6

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)	3 Months Ended
	Mar. 31, 2019reporting_unit
Accounting Policies [Abstract]
Number of reporting units	3

Basis of Presentation, Summar_7

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)	3 Months Ended
	Mar. 31, 2019
Corporate trade name | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
Corporate trade name | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life	25 years
Technology
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years
Provider network contracts
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years

Recently Issued Accounting St_2

Recently Issued Accounting Standards (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets - operating	$ 63,855
Right-of-use liabilities - operating	60,636
Cumulative effect on retained earnings	$ 3,270		$ 50,009
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets - operating		$ 51,400
Right-of-use liabilities - operating		$ 47,400
Impact of adoption Higher/(Lower) | Accounting Standards Update 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect on retained earnings				$ 17,300

Transactions - New Century Heal

Transactions - New Century Health (Details) - USD ($) $ in Thousands, shares in Millions	Oct. 01, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Nov. 30, 2018	Oct. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Aug. 31, 2017
Purchase consideration:
Cash		$ 6,000	$ 11,676
Liabilities assumed:
Goodwill		$ 770,334		$ 768,124				$ 628,186
Customer relationships | Minimum
Liabilities assumed:
Useful life		10 years
Customer relationships | Maximum
Liabilities assumed:
Useful life		25 years
Technology
Liabilities assumed:
Useful life		5 years
Corporate trade name | Minimum
Liabilities assumed:
Useful life		10 years
Corporate trade name | Maximum
Liabilities assumed:
Useful life		20 years
Provider network contracts
Liabilities assumed:
Useful life		5 years
New Century Health
Business Acquisition [Line Items]
Percentage of voting interests acquired	100.00%
Total merger consideration, net of cash on hand and certain closing adjustments	$ 205,100
Payments to acquire businesses, net	118,700
Contingent consideration arrangements (up to)	20,000
Contingent consideration arrangements fair value	3,200
Transaction costs				1,600
Purchase consideration:
Cash	124,652
Fair value of Class B common stock issued	83,173
Fair value of contingent consideration	3,200
Total consideration	211,025
Tangible assets acquired:
Cash and cash equivalents	5,963
Accounts receivable	5,559
Prepaid expenses and other current assets	7,901
Property and equipment	381
Other noncurrent assets	148
Liabilities assumed:
Accounts payable	1,167
Accrued liabilities	1,494
Accrued compensation and employee benefits	3,966
Reserves for claims and performance-based arrangements	18,631
Deferred tax liabilities	24,041
Other long-term liabilities	6,138
Goodwill	133,110
Net assets acquired	$ 211,025
New Century Health | Class B
Business Acquisition [Line Items]
Consideration transferred, equity interests issued and issuable, shares issued (in shares)	3.1
Contingent consideration arrangements (up to)	$ 11,400
New Century Health | Selling, general and administrative expenses
Business Acquisition [Line Items]
Transaction costs				$ 1,600
New Century Health | Customer relationships
Identifiable intangible assets acquired:
Identifiable intangible assets	$ 72,500
New Century Health | Customer relationships | Minimum
Liabilities assumed:
Useful life	15 years
New Century Health | Technology
Identifiable intangible assets acquired:
Identifiable intangible assets	$ 27,000
Liabilities assumed:
Useful life	5 years
New Century Health | Corporate trade name
Identifiable intangible assets acquired:
Identifiable intangible assets	$ 4,300
Liabilities assumed:
Useful life	10 years
New Century Health | Provider network contracts
Identifiable intangible assets acquired:
Identifiable intangible assets	$ 9,600
Liabilities assumed:
Useful life	5 years
Former Owners Of New Century Health | New Century Health
Business Acquisition [Line Items]
Contingent consideration arrangements (up to)	$ 11,400
Former Employees of New Century Health | New Century Health
Business Acquisition [Line Items]
Contingent consideration arrangements (up to)	$ 8,600
Evolent Health LLC
Business Acquisition [Line Items]
Parent's ownership percentage	95.30%	96.10%	98.90%		96.10%	95.30%	99.00%		96.60%

Transactions - New Mexico Healt

Transactions - New Mexico Health Connections (Details) - USD ($) $ in Thousands	Jan. 02, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Purchase consideration:
Payments to acquire businesses		$ 6,000	$ 11,676
Identifiable intangible assets acquired and liabilities assumed
Goodwill		$ 770,334		$ 768,124	$ 628,186
Provider network contracts
Identifiable intangible assets acquired and liabilities assumed
Useful life		5 years
New Mexico Health Connections
Business Acquisition [Line Items]
Transaction costs					$ 1,200
Purchase consideration:
Payments to acquire businesses	$ 10,000
Contingent consideration, liability	252
Consideration transferred	10,252
Identifiable intangible assets acquired and liabilities assumed
Accrued compensation and employee benefits	(474)
Goodwill	5,826
Net assets acquired	10,252
New Mexico Health Connections | Customer relationships
Identifiable intangible assets acquired and liabilities assumed
Identifiable intangible assets	$ 2,700
Useful life	15 years
New Mexico Health Connections | Provider network contracts
Identifiable intangible assets acquired and liabilities assumed
Identifiable intangible assets	$ 2,300
Useful life	5 years
New Mexico Health Connections | Above market lease
Identifiable intangible assets acquired and liabilities assumed
Identifiable intangible assets	$ (100)

Transactions - Pro Forma Inform

Transactions - Pro Forma Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenue	$ 197,756	$ 184,630
Net income (loss)	(48,649)	(14,885)
Net income (loss) attributable to non-controlling interests	(1,881)	(972)
Net income (loss) attributable to Evolent Health, Inc.	$ (46,768)	$ (13,913)
Net income (loss) available to common shareholders, basic (in dollars per share)	$ (0.59)	$ (0.18)
Net income (loss) available to common shareholders, diluted (in dollars per share)	$ (0.59)	$ (0.18)
New Century Health
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Adjustment for removal of transaction costs			$ 1,600

Transactions - Securities Offer

Transactions - Securities Offerings and Sales (Details) - shares	1 Months Ended
	Nov. 30, 2018	Mar. 31, 2018	Mar. 31, 2019	Dec. 31, 2018	Oct. 31, 2018	Oct. 01, 2018	Sep. 30, 2018	Jun. 30, 2018	Aug. 31, 2017
Class A
Organization [Line Items]
Common stock, outstanding (in shares)			79,428,728	79,172,118
Class A | Common Stock
Organization [Line Items]
Issuance of common stock (in shares)	800,000	3,000,000
Class A | Common Stock | Evolent Health, Selling Stockholders
Organization [Line Items]
Issuance of common stock (in shares)	100,000	1,200,000
Class A | Common Stock | Investor Stockholders
Organization [Line Items]
Issuance of common stock (in shares)		1,800,000
Common stock, outstanding (in shares)								0
Class A | Common Stock | TPG
Organization [Line Items]
Issuance of common stock (in shares)	700,000
Evolent Health LLC
Organization [Line Items]
Parent's ownership percentage	96.10%	98.90%	96.10%		95.30%	95.30%	99.00%		96.60%

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Revenues		$ 197,756	$ 139,714
Transformation services
Disaggregation of Revenue [Line Items]
Revenues	[1]	3,353	6,505
Platform and operations services
Disaggregation of Revenue [Line Items]
Revenues		147,292	109,818	[1]
Services | Transformation services
Disaggregation of Revenue [Line Items]
Revenues		3,353	6,505
Services | Platform and operations services
Disaggregation of Revenue [Line Items]
Revenues		$ 147,292	$ 108,420
[1]	See Note 17 for amounts related to related parties included in these line items.

Revenue Recognition - Transacti

Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details) $ in Millions	Mar. 31, 2019USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation	$ 84.6
Revenue, remaining performance obligation, percent to be recognized in current fiscal year	56.00%
Revenue, remaining performance obligation, percent to be recognized in next fiscal year	88.00%

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Short-term receivables	$ 63,886	$ 78,380
Long-term receivables	6,550	6,550
Short-term contract assets	1,282	2,102
Long-term contract assets	1,695	961
Short-term deferred revenue	22,320	20,584
Long-term deferred revenue	443	$ 1,502
Contract assets
Balance as of beginning-of-period	3,063
Reclass to receivables, as the right to consideration becomes unconditional	(1,183)
Contract assets recognized, net of reclass to receivables	1,097
Balance as of end-of-period	2,977
Deferred revenue
Balance as of beginning-of-period	22,086
Reclass to revenue, as a result of performance obligations satisfied	(11,807)
Cash received in advance of satisfaction of performance obligations	12,484
Balance as of end-of-period	$ 22,763

Revenue Recognition - Contrac_2

Revenue Recognition - Contract Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Capitalized Contract Cost [Line Items]
Contract cost amortization	$ 1,250	$ 570
Capitalized contract cost, amortization period	5 years
Bonuses and Commissions
Capitalized Contract Cost [Line Items]
Contract cost assets	$ 2,500		$ 1,500
Contract cost amortization	100
Contract Fulfillment Costs
Capitalized Contract Cost [Line Items]
Contract cost assets	20,000		$ 17,600
Contract cost amortization	$ 1,200	$ 500

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 114,371		$ 105,366
Accumulated depreciation and amortization	(36,992)		(31,738)
Total property and equipment, net	77,379		73,628
Depreciation expense	5,200	$ 3,600
Capitalized computer software, amortization	4,100	2,500
Computer hardware
Property, Plant and Equipment [Line Items]
Total property and equipment	10,850		10,421
Furniture and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	3,226		3,187
Internal-use software development costs
Property, Plant and Equipment [Line Items]
Total property and equipment	90,284		81,640
Total property and equipment, net	67,400		62,800
Capitalized computer software additions	8,700	$ 10,500
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 10,011		$ 10,118

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Goodwill (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019USD ($)reporting_unit	Dec. 31, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Number of reporting units | reporting_unit	3
Goodwill [Roll Forward]
Balance as of beginning-of-period	$ 768,124	$ 628,186
Goodwill Acquired	2,200	140,169
Measurement period adjustment, goodwill	0	(117)
Foreign currency translation	10	(114)
Balance as of end-of-period	770,334	768,124
Accumulated impairment	160,600	160,600
Services
Goodwill [Roll Forward]
Balance as of beginning-of-period	762,419	628,186
Goodwill Acquired	2,200	134,343
Measurement period adjustment, goodwill	0	4
Foreign currency translation	10	(114)
Balance as of end-of-period	764,629	762,419
True Health
Goodwill [Roll Forward]
Balance as of beginning-of-period	5,705	0
Goodwill Acquired	0	5,826
Measurement period adjustment, goodwill	0	(121)
Foreign currency translation	0	0
Balance as of end-of-period	$ 5,705	$ 5,705

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 413,738		$ 403,438
Accumulated Amortization	77,507		68,402
Net Carrying Value	336,231		$ 335,036
Amortization of intangible assets	$ 9,100	$ 5,900
Corporate trade name
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life	14 years 11 months 5 days		15 years 2 months 26 days
Gross Carrying Amount	$ 23,300		$ 23,300
Accumulated Amortization	3,856		3,511
Net Carrying Value	$ 19,444		$ 19,789
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life	17 years 7 months 15 days		18 years 1 month 15 days
Gross Carrying Amount	$ 291,519		$ 281,219
Accumulated Amortization	32,818		29,184
Net Carrying Value	$ 258,701		$ 252,035
Technology
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life	2 years 8 months 20 days		3 years
Gross Carrying Amount	$ 82,922		$ 82,922
Accumulated Amortization	36,261		31,764
Net Carrying Value	$ 46,661		$ 51,158
Below market lease, net
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life	3 years 9 months 25 days		4 years
Gross Carrying Amount	$ 4,097		$ 4,097
Accumulated Amortization	3,037		3,003
Net Carrying Value	$ 1,060		$ 1,094
Provider network contracts
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Remaining Useful Life	4 years 5 months 5 days		4 years 7 months 15 days
Gross Carrying Amount	$ 11,900		$ 11,900
Accumulated Amortization	1,535		940
Net Carrying Value	$ 10,365		$ 10,960

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Schedule of Future Estimated Amortization (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2019	$ 28,419
2020	33,309
2021	29,173
2022	25,292
2023	22,528
Thereafter	197,510
Net Carrying Value	$ 336,231	$ 335,036

Long-term Debt - 2025 Notes (De

Long-term Debt - 2025 Notes (Details) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended
	Oct. 31, 2018USD ($)shares$ / shares	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Oct. 24, 2018USD ($)	Oct. 22, 2018USD ($)
Debt Instrument [Line Items]
Carrying amount		$ 223,320,000	$ 221,041,000
Senior Convertible Notes due 2025
Debt Instrument [Line Items]
Debt issuance costs	$ 5,900,000
Senior Notes | Senior Convertible Notes due 2025
Debt Instrument [Line Items]
Face amount	$ 172,500,000	172,500,000	$ 172,500,000	$ 22,500,000	$ 150,000,000
Interest rate	1.50%
Proceeds from issuance of debt	$ 166,600,000
Debt issuance costs	3,400,000
Interest expense		600,000
Debt conversion denominator shares per principal amount	$ 1,000
Conversion price (in dollars per share) | $ / shares	$ 33.43
Initial conversion amount (in shares) | shares	5.2
Carrying amount	$ 100,700,000
Non-cash amortization of debt discount and debt issuance costs		$ 2,000,000
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount	100.00%
Repurchase covenant, sale price as a percentage of conversion price	130.00%
Repurchase covenant, trading days (at least)	20 days
Repurchase covenant, consecutive trading days, minimum	30 days
Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price	100.00%
Senior Notes | Senior Convertible Notes due 2025 | Common Stock
Debt Instrument [Line Items]
Proceeds from issuance of debt	$ 71,800,000
Senior Notes | Senior Convertible Notes due 2025 | Class A Common Stock | Common Stock
Debt Instrument [Line Items]
Initial conversion rate per $1000 principal amount	0.0299135

Long-term Debt - 2021 Notes (De

Long-term Debt - 2021 Notes (Details) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended
	Dec. 31, 2016USD ($)shares$ / shares	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
Amortization of deferred financing costs (2016 - less than)		$ 2,279,000	$ 229,000
Senior Notes | Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Face amount	$ 125,000,000	125,000,000		$ 125,000,000
Interest rate	2.00%
Proceeds from issuance of debt	$ 120,400,000
Debt issuance costs	$ 4,600,000
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount	100.00%
Interest expense		$ 600,000
Amortization of deferred financing costs (2016 - less than)			$ 200,000
Debt conversion denominator shares per principal amount	$ 1,000
Class A Common Stock | Common Stock | Senior Notes | Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Initial conversion rate per $1000 principal amount	0.0416082
Conversion price (in dollars per share) | $ / shares	$ 24.03
Initial conversion amount (in shares) | shares	5.2

Long-term Debt - Convertible Se

Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Oct. 31, 2018	Oct. 24, 2018	Oct. 22, 2018	Dec. 31, 2016
Senior Convertible Notes due 2025
Debt Instrument [Line Items]
Carrying value	$ 100,779,000	$ 98,730,000
Unamortized debt discount and issuance costs allocated to debt	71,721,000	73,770,000
Principal amount	$ 172,500,000	$ 172,500,000	$ 172,500,000	$ 22,500,000	$ 150,000,000
Remaining amortization period	6 years 6 months	6 years 10 months
Senior Convertible Notes due 2025 | Level 2
Debt Instrument [Line Items]
Fair value	$ 136,700,000	$ 158,800,000
Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Carrying value	122,541,000	122,311,000
Unamortized debt discount and issuance costs allocated to debt	2,459,000	2,689,000
Principal amount	$ 125,000,000	$ 125,000,000				$ 125,000,000
Remaining amortization period	2 years 8 months 25 days	2 years 10 months 25 days
Convertible Senior Notes due 2021 | Level 2
Debt Instrument [Line Items]
Fair value	$ 121,400,000	$ 133,600,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Mar. 31, 2019	Mar. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]
Operating capital support commitment, maximum amount	$ 11,000,000			$ 11,000,000
Carrying amount	221,041,000			223,320,000
Restricted funds	$ 160,823,000			$ 57,956,000	$ 36,757,000
Tax receivables agreement, percent of tax savings to be paid				85.00%
New Mexico Health Connections
Restricted Cash and Cash Equivalents Items [Line Items]
Reinsurance arrangement, term	15 months	15 months
Reinsurance arrangement, capital amount		$ 10,000,000
Reinsurance arrangement, quarterly fee		200,000
Reinsurance arrangement, percentage of gross premiums ceded	90.00%
Reinsurance arrangement, percentage of claims liability indemnified	90.00%
Reinsurance arrangement, maximum amount of insurance risk as a percentage of premiums ceded	105.00%
Letters of credit for facility leases
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds	$ 3,710,000			$ 3,710,000
Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds	34,142,000			37,691,000
Collateral for reinsurance agreement | New Mexico Health Connections
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds		$ 10,000,000
Minimum
Restricted Cash and Cash Equivalents Items [Line Items]
Letters of credit outstanding, minimum				3,700,000
Letter of Credit | Line of Credit
Restricted Cash and Cash Equivalents Items [Line Items]
Line of credit, maximum borrowing capacity			$ 5,000,000
Line of credit, quarterly rental fee percentage			0.80%
Carrying amount	$ 0			$ 0

Commitments and Contingencies_2

Commitments and Contingencies - Reinsurance Agreement (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period	$ 1,243
Reinsurance premiums assumed	25,441
Claims assumed	21,151
Claims-related administrative expenses	4,282
(Increase) decrease in claims reserves attributable to the Reinsurance Agreement	8
Reinsurance payments	1,243
Receivables for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period	$ 8

Commitments and Contingencies_3

Commitments and Contingencies - Concentration Risk (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Concentration Risk [Line Items]
Percentage of cash and cash equivalents held with FDIC participating banks	80.30%
Cash and cash equivalents (including restricted cash)	$ 227.5
Percentage of cash and cash equivalents held in money market funds	19.30%
Percentage of cash held in international banks (less than)	1.00%
Customer C | Customer Concentration Risk | Accounts Receivable | Customer Receivable
Concentration Risk [Line Items]
Concentration risk	15.40%		23.30%
Customer C | Customer Concentration Risk | Revenue
Concentration Risk [Line Items]
Concentration risk		10.60%
Customer A | Customer Concentration Risk | Revenue
Concentration Risk [Line Items]
Concentration risk	14.00%
Customer B | Customer Concentration Risk | Revenue
Concentration Risk [Line Items]
Concentration risk	13.10%	20.10%

Leases (Components of Lease Exp

Leases (Components of Lease Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Leases [Abstract]
Operating lease cost	$ 3,281
Variable lease cost	1,455
Total lease cost	$ 4,736
Rent expense, net of sublease income		$ 3,300

Leases (Maturity of Lease Liabi

Leases (Maturity of Lease Liabilities) (Details) $ in Thousands	Mar. 31, 2019USD ($)
Leases [Abstract]
2019	$ 5,226
2020	8,613
2021	8,719
2022	7,563
2023	7,414
2024 and thereafter	47,118
Total lease payments	84,653
Less:
Interest	24,017
Present value of lease liabilities	60,636
Lessee, operating lease, lease not yet commenced, undiscounted amount	$ 31,100

Leases (Weighted-average Discou

Leases (Weighted-average Discount Rate and Weighted-remaining Lease Terms) (Details)	Mar. 31, 2019
Leases [Abstract]
Weighted average discount rate	6.25%
Weighted average remaining lease term	9 years 8 months 16 days

Earnings (Loss) Per Common Sh_3

Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Earnings Per Share [Abstract]
Net income (loss)	$ (48,649)	$ (14,065)
Less:
Net income (loss) attributable to non-controlling interests	(1,910)	(439)
Net income (loss) available for common shareholders	$ (46,739)	$ (13,626)
Weighted-average common shares outstanding (in shares)	79,335,000	75,375,000
Earnings (Loss) per Common Share
Basic (in dollars per share)	$ (0.59)	$ (0.18)
Diluted (in dollars per share)	$ (0.59)	$ (0.18)
Class B
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Convertible preferred stock, shares issued upon conversion (in shares)	1

Earnings (Loss) Per Common Sh_4

Earnings (Loss) Per Common Share - Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	16,560	10,131
Exchangeable Class B common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	3,190	2,141
Restricted stock units (RSUs), performance-based RSUs and leveraged stock units (LSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	1,043	627
Stock options and performance-based stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	1,966	2,162
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share (in shares)	10,361	5,201

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 4,537,000	$ 3,795,000
Share-based compensation expense capitalized as software development costs	0	0
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	791,000	316,000
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	3,746,000	3,479,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,360,000	2,231,000
Performance-based stock options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	110,000	110,000
RSUs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	2,430,000	1,454,000
Performance-based RSUs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	384,000	0
LSUs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 253,000	$ 0

Stock-based Compensation - Awar

Stock-based Compensation - Awards Granted (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based awards granted (in shares)	381,000	962,000
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based awards granted (in shares)	501,000	753,000
LSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based awards granted (in shares)	720,000	0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income tax expense (benefit) (less than $0.1 million for nine months ended March 31, 2018)	$ (496)	$ 3
Effective tax rate	1.00%	(0.10%)
Unrecognized tax benefits			$ 900
Tax receivables agreement, percent of tax savings to be paid	85.00%

Investments In and Advances t_2

Investments In and Advances to Equity Method Investees (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Loss from affiliates	$ 424	$ 131
Equity Method Investee | Services Agreements
Schedule of Equity Method Investments [Line Items]
Revenue related to long-term services agreement (less than $0.1 million - 3 months ended March 31, 2018)	$ 7,100	$ 100
Minimum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage	4.00%		4.00%
Equity method investment, ownership percentage	4.00%		4.00%
Maximum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage	40.00%		40.00%
Equity method investment, ownership percentage	40.00%		40.00%

Non-controlling Interests (Deta

Non-controlling Interests (Details) - USD ($) $ in Thousands, shares in Millions	Oct. 01, 2018	Nov. 30, 2018	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Oct. 31, 2018	Sep. 30, 2018	Aug. 31, 2017
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests as of beginning-of-period				$ 45,532
Net income (loss) attributable to non-controlling interests				(1,910)	$ (439)
Non-controlling interests as of end-of-period				50,100
Non-controlling Interests
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests as of beginning-of-period				45,532	35,427
Cumulative-effect adjustment from adoption of new accounting principle				0	594
Decrease in non-controlling interests as a result of Class B Exchanges				0	(23,805)
Amount attributable to NCI from 2019 business combination				6,500	0
Net income (loss) attributable to non-controlling interests				(1,910)	(439)
Reclassification of non-controlling interests				(22)	(5)
Non-controlling interests as of end-of-period			$ 11,772	$ 50,100	$ 11,772
Class A | Common Stock
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)		0.8	3
Class A | Investor Stockholders | Common Stock
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)			1.8
Class A | TPG | Common Stock
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)		0.7
Class A | Evolent Health, Selling Stockholders | Common Stock
Noncontrolling Interest [Line Items]
Issuance of common stock (in shares)		0.1	1.2
Evolent Health LLC
Noncontrolling Interest [Line Items]
Parent's ownership percentage	95.30%	96.10%	98.90%	96.10%	98.90%	95.30%	99.00%	96.60%
New Century Health | Class B
Noncontrolling Interest [Line Items]
Consideration transferred, shares issued (in shares)	3.1

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Oct. 01, 2018
Recurring
Assets
Cash and cash equivalents	$ 9,139	$ 11,391
Restricted cash and restricted investments	34,774	31,226
Total	43,913	42,617
Liabilities
Contingent consideration, liability	8,100	8,800
Recurring | Level 1
Assets
Cash and cash equivalents	9,139	11,391
Restricted cash and restricted investments	34,774	31,226
Total	43,913	42,617
Liabilities
Contingent consideration, liability	0	0
Recurring | Level 2
Assets
Cash and cash equivalents	0	0
Restricted cash and restricted investments	0	0
Total	0	0
Liabilities
Contingent consideration, liability	0	0
Recurring | Level 3
Assets
Cash and cash equivalents	0	0
Restricted cash and restricted investments	0	0
Total	0	0
Liabilities
Contingent consideration, liability	8,100	8,800
Passport | Recurring
Liabilities
Contingent consideration, liability	4,900	5,600
New Century Health
Liabilities
Contingent consideration arrangements (up to)			$ 20,000
New Century Health | Recurring
Liabilities
Contingent consideration, liability	$ 3,200	$ 3,200
Class B | New Century Health
Liabilities
Contingent consideration arrangements (up to)			$ 11,400

Fair Value Measurement - Change

Fair Value Measurement - Changes in Contingent Consideration (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance as of beginning of period	$ 8,800	$ 8,700
Settlements	(800)	0
Realized and unrealized (gains) losses, net	100	100
Balance as of end of period	$ 8,100	$ 8,800

Fair Value Measurement - Valuat

Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Fair Value	$ 8,100	$ 8,800	$ 8,800	$ 8,700
Level 3 | Real options approach 2017-2021 | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted recurring revenue compound annual growth rate, period	5 years
Recurring | Level 3 | Real options approach 2017-2021 | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-adjusted recurring revenue compound annual growth rate, period	5 years
Recurring | Level 3 | Real options approach 2017-2021 | Risk-adjusted recurring revenue CAGR | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Theoretical recurring revenue	$ 1,000
Recurring | Level 3 | Real options approach 2019-2021 | Risk-adjusted recurring revenue CAGR | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	0.618
Recurring | Passport | Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Fair Value	$ 4,900	$ 5,600
Recurring | Passport | Level 3 | Real options approach | Risk-adjusted recurring revenue CAGR | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	1.039	1.039
Recurring | Passport | Level 3 | Real options approach | Discount rate | Contingent consideration | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	0.055	0.055
Recurring | Passport | Level 3 | Real options approach | Discount rate | Contingent consideration | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	0.065	0.065
Recurring | New Century Health | Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Fair Value	$ 3,200	$ 3,200
Recurring | New Century Health | Level 3 | Real options approach | Risk-neutral probability exceeds threshold | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	0.390	0.390
Recurring | New Century Health | Level 3 | Real options approach | Risk-neutral probability meets earn-out cap | Contingent consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or Input Ranges	0.240	0.240

Related Parties (Details)

Related Parties (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Equity Method Investee | Services Agreements
Related Party Transaction [Line Items]
Revenue related to long-term services agreement (less than $0.1 million - 3 months ended March 31, 2018)	$ 7.1	$ 0.1

Related Parties - Revenues and

Related Parties - Revenues and Expenses (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Revenue
Revenues		$ 197,756	$ 139,714
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)	[1]	117,441	71,975
Selling, general and administrative expenses		74,838	55,526	[1]
Affiliates
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses)		7,830	3,190
Selling, general and administrative expenses		156	99
Transformation services
Revenue
Revenues	[1]	3,353	6,505
Transformation services | Affiliates
Revenue
Revenues		1,159	32
Platform and operations services
Revenue
Revenues		147,292	109,818	[1]
Platform and operations services | Affiliates
Revenue
Revenues		$ 12,944	$ 7,291
[1]	See Note 17 for amounts related to related parties included in these line items.

Segment Reporting (Details)

Segment Reporting (Details) $ in Thousands		3 Months Ended
		Mar. 31, 2019USD ($)segment	Mar. 31, 2018USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment		2
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		$ 197,756	$ 139,714
Adjusted EBITDA		(14,778)	7,913
Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		153,704	120,120
Adjusted EBITDA		(15,499)	6,966
Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		47,376	23,585
Adjusted EBITDA		721	947
Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(3,324)	(3,991)
Transformation services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	[1]	3,353	6,505
Transformation services | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		3,353	6,505
Transformation services | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		3,353	6,505
Transformation services | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0
Transformation services | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0
Platform and operations services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		147,292	109,818	[1]
Platform and operations services | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		147,292	108,420
Platform and operations services | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		150,351	113,615
Platform and operations services | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0
Platform and operations services | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(3,059)	(3,797)
Services revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		150,645	116,323
Services revenue | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		153,704	120,120
Services revenue | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0
Services revenue | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(3,059)	(3,797)
Premiums
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		47,111	23,391
Premiums | Operating segments | Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0
Premiums | Operating segments | True Health
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		47,376	23,585
Premiums | Intersegment eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		$ (265)	$ (194)
[1]	See Note 17 for amounts related to related parties included in these line items.

Segment Reporting - Reconciliat

Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment Reporting [Abstract]
Net Income (Loss) Attributable to Evolent Health, Inc.	$ (46,739)	$ (13,626)
Interest income	1,060	1,072
Interest expense	(3,562)	(853)
(Provision) benefit for income taxes	496	(3)
Depreciation and amortization expenses	(14,266)	(9,496)
Income (loss) from equity method investees	(424)	(131)
Change in fair value of contingent consideration	(100)	(100)
Other income (expense), net	427	(18)
Net income (loss) attributable to non-controlling interests	1,910	439
ASC 606 transition adjustments	0	(4,498)
Purchase accounting adjustments	(596)	(217)
Stock-based compensation expense	(4,537)	(3,795)
Severance costs	(10,602)	(1,594)
Amortization of contract cost assets	(754)	(561)
Transaction costs	(1,013)	(1,784)
Adjusted EBITDA	$ (14,778)	$ 7,913

Reserves for Claims and Perfo_3

Reserves for Claims and Performance-Based Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]
Beginning balance	$ 27,595	$ 0
Incurred costs related to:
Current year	65,275	16,749
Prior years	13,138	0
Total incurred	78,413	16,749
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]
Current year	40,366	10,050
Prior years	14,027	0
Total paid	54,393	10,050
Other adjustments	(21,596)	0
Change during the year	2,424	6,699
Ending balance	30,019	6,699
Services
Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]
Beginning balance	17,715	0
Incurred costs related to:
Current year	33,777	0
Prior years	6,879	0
Total incurred	40,656	0
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]
Current year	28,684	0
Prior years	6,871	0
Total paid	35,555	0
Other adjustments	(438)	0
Change during the year	4,663	0
Ending balance	22,378	0
True Health
Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]
Beginning balance	9,880	0
Incurred costs related to:
Current year	31,498	16,749
Prior years	6,259	0
Total incurred	37,757	16,749
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]
Current year	11,682	10,050
Prior years	7,156	0
Total paid	18,838	10,050
Other adjustments	(21,158)	0
Change during the year	(2,239)	6,699
Ending balance	$ 7,641	$ 6,699

Investments - Investment Summar

Investments - Investment Summary (Details) - Level 2 - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	$ 13,789	$ 10,010
Gross Unrealized Gains	292	154
Gross Unrealized Losses	0	0
Fair Value	14,081	10,164
U.S. Treasury bills
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	10,388	7,982
Gross Unrealized Gains	211	120
Gross Unrealized Losses	0	0
Fair Value	10,599	8,102
Corporate bonds
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	1,090	887
Gross Unrealized Gains	37	17
Gross Unrealized Losses	0	0
Fair Value	1,127	904
Other CMOs
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	1,715	545
Gross Unrealized Gains	21	6
Gross Unrealized Losses	0	0
Fair Value	1,736	551
Yankees
Schedule of Held-to-maturity Securities [Line Items]
Amortized Costs	596	596
Gross Unrealized Gains	23	11
Gross Unrealized Losses	0	0
Fair Value	$ 619	$ 607

Investments - Contractual Matur

Investments - Contractual Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Amortized Cost
Due in one year or less	$ 2,046	$ 0
Due after one year through five years	11,743	9,666
Due after five years through ten years	0	344
Total	13,789	10,010
Fair Value
Due in one year or less	2,050	0
Due after one year through five years	12,031	9,813
Due after five years through ten years	0	351
Total	$ 14,081	$ 10,164

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Supplemental disclosure of cash flow information
Operating cash flows from operating leases	$ 4,165	$ 0
Leased assets obtained in exchange for new finance lease liabilities	14,917	0
Non-cash investing and financing activities
Accrued property and equipment purchases	487	3,183
Class A common stock issued for payment of Passport earn-out	800	0
Consideration for asset acquisitions or business combinations	0	500
Settlement of escrow related to asset acquisition	0	2,519
Effects of Class B Exchanges
Decrease in deferred tax liability as a result of securities offerings	0	23,805
Decrease in deferred tax liability as a result of securities offerings	$ 0	$ 908

Uncategorized Items - evh-20190

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 17,309,000
Noncontrolling Interest [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	594,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 16,715,000